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1 Introduction
During the last decades the number of people suffering from heart
and circulatory diseases has been growing. The generic term for
these diseases is Congestive Heart Failure (CHF): the inability of
the heart to pump blood effectively through the body (or requiring
elevated filling pressures in order to pump effectively).
Surgical procedures, such as heart valve replacement and bypass
operations, as well as medication treatment, such as beta blockers
and ACE (Angiotensin-Converting Enzyme) inhibitors are esta-
blished therapies to treat CHF. Both medications have a blood
pressure-lowering effect. When these therapies are unsuccessful,
the heart of the patient will deteriorate to such an extent that only
a heart transplantation remains as the only non-mechanical solu-
tion. However, the number of candidates exceeds far the number
of available donor hearts. Mechanical circulatory support systems
are being developed to fill this gap. They support the heart and
cardiovascular system until an appropriate donor heart is availa-
ble. As experience is gained and technology has advanced, me-
chanical circulatory support has demonstrated to be an effective
alternative for an increasing number of indications (REMATCH
trial, (Rose EA, 1999)): support of the heart until it is fully re-
covered (bridge to recovery) and long term heart/cardiovascular
support (destination therapy).
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Mechanical circulatory support can be divided into two different
types:
• Ventricular Assist Device (VAD): this type of support assists
the failing heart and is implanted parallel to the left, right
or both sides of the heart.
• Total Artificial Heart (TAH): this type of support replaces
the failing heart anatomically and functionally.
At the Helmholtz Institute, two implantable electromechanical
displacement blood pumps are being developed: the total artificial
heart ACcor and the ventricular assist device VERSUS. ACcor has
not been submitted to animal experiments yet, whereas VERSUS
supported the left ventricle of a calf during 10 days in one chronic
experiment. The previous development steps of these devices have
been described in PhD theses (Kaufmann, 1996) and (Foerster,
2003) respectively.
The development of VAD’s or TAH’s is driven by clinical de-
mand. Clinical specialists encounter different clinical indications
and define for which purpose the device has to be developed. The
main development phases of ACcor and VERSUS are:
1. Conceptual phase: from the definition of the functional spe-
cifications till the proof of concept: a conceptual bench type
that fulfills the main requirements of the future device as
stated in the functional specifications.
2. Design phase: an iterative process between extensive valida-
tion experiments and redesigns to reach design freeze: the
stage, which obviates the need for further design alterations
as it is assumed that the current design will successfully fulfill
all requirements for the product.
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3. Production set-up and approval phase: from design freeze till
market approval. First, the entire supply, manufacturing and
production process of the device is set-up and fixed. The se-
cond step is to obtain Food and Drug Administration (FDA)
approval (U.S.A.) or CE Marking (Europe), after which the
device can be sold.
Experience at the Helmholtz institute demonstrates that the
development of devices, such as ACcor and VERSUS, is usually
transferred into the industry before design freeze is reached.
The present dissertation discusses the development steps per-
formed with ACcor and VERSUS starting from the first successful
animal experiment (design phase). The applied design and vali-
dation methods in order to improve and determine the functio-
ning of device will be presented and discussed. Finally, a concept
to systematically design and validate ACcor and VERSUS in the
conceptual and design phase is presented.
The structure of this dissertation is as follows:
Chapter 2 introduces the reader to the clinical and technical
background of VAD and TAH systems. ACcor and VERSUS are
presented more in detail and the development of blood pumps is
discussed in general.
Chapter 3 and Chapter 4 discuss the performed development
steps with ACcor and VERSUS respectively. All performed vali-
dation methods and their consequent redesigns are presented.
Chapter 5 presents the development of a wireless data acquisi-
tion system. It was developed for long term animal experiments,
because a complete freedom of movement of the animal after seven
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days was desired by the ethics committee of the local government
in Cologne. This chapter demonstrates also how initial unexpected
requirements may delay the development of blood pumps.
Chapter 6 presents a concept to systematically design and va-
lidate ACcor and VERSUS in the conceptual and design phase.
Also, an overview of the complete development process is included.
The summary and perspective complete the dissertation, fol-
lowed by the literature index and appendices.
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2 Clinical and technical
background
Heart failure has been the leading cause of death in industrialised
countries for several decades. Together with cancer, they account
for over half of all deaths (Tab. 2.1). When conventional therapies
do not suffice, blood pumps can be used to support or replace the
failing heart for patient survival. For better understanding of the
basics and conditions for the development of blood pumps, their
medical and technical background will be explained more in detail.
2.1 Clinical background
The heart is the central organ of the cardiovascular system. Its
main function is to maintain the blood circulation by pumping ap-
Cause of death U.S.A Germany
Heart and circulatory diseases 859,619 (35%) 338,222 (45%)
Malignant neoplasms (cancer) 557,271 (23%) 209,477 (26%)
Respiratory diseases 124,816 (5%) 52,369 (6%)
Accidents (unintent. injuries) 106,742 (4%) 33 549 (4%)
Other 721,690 (33%) 154,653 (17%)
Table 2.1: Causes of death in the United States of America
(2002) and Germany (2004) (Destatis, 2005), (Kochanek KD,
2004)
5
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Figure 2.1: Anatomy of the natural heart: (1) right ventri-
cle, (2) right atrium, (3) vena cava, (4) aorta, (5) pulmonary
artery, (6) pulmonary vein, (7) left atrium, (8) left ventricle,
(a) tricuspid valve, (b) pulmonary valve, (c) aortic valve, (d)
mitral valve.
proximately five liters of blood each minute when the person is
at rest. The cardiovascular system consists of a major (systemic)
and minor (pulmonary) circulation. The major circulatory net-
work is the bloodstream through the organs and limbs, delivering
oxygen and nutrients to body organs and removing waste products
of metabolism from tissue cells. The minor circulatory network is
the bloodstream through the lungs, where the blood is enriched
with oxygen.
The heart is divided into four chambers (Fig. 2.1): right atrium,
left atrium, right ventricle and left ventricle. The right atrium and
right ventricle are responsible for pumping oxygen-poor blood into
the lungs. The left atrium and the left ventricle supply oxygen-
6
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rich blood to the organs and muscles. Blood in the heart is kept
flowing in a forward direction by a system of four one way valves,
each one closing off one of the heart chambers at the appropriate
time in the cardiac cycle. The size of a healthy human heart is
approximately that of one closed fist (dimensions: 13cm x 9cm x
6cm). It is cone-shaped and weighs approximately 300 grams.
The cardiac output of the left ventricle is larger than that from
the right ventricle. The main cause is the bronchial shunt. A
small percentage of blood expelled by the left ventricle enters the
bronchial arteries, which originate from the mid-thoracic aorta.
This blood delivers nutrients to the pulmonary tissues (bronchi)
and enters the pulmonary veins via bronchopulmonary anasto-
moses. Then, it returns directly to the left ventricle and hence
bypasses the right side of the heart. The difference in ventricular
output depends on activity of the person (sleep, awake or walking)
and lies in the range of 0% and 10%.
2.1.1 Pathophysiology
The most common term to designate a sick heart is CHF (Chronic
Heart Failure): the inability of the heart to pump blood effec-
tively through the body, or requiring elevated filling pressures in
order to pump effectively. The most common used classification
for graduation of CHF has been defined by the New York Heart
Association (NYHA) (de Gruyter, 1998):
I. No symptoms and no limitation in ordinary physical activity.
II. Mild symptoms and slight limitation during ordinary acti-
vity. Comfortable at rest.
7
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III. Marked limitation in activity due to symptoms, even during
less-than-ordinary activity. Comfortable only at rest.
IV. Severe limitations. Experiences symptoms even while at rest.
Several heart and circulatory diseases can lead to chronic heart
failure. The most common diseases are:
• Coronary artery disease: narrowed arteries reducing blood
supply to the heart muscle.
• Myocardial infarction, that leads to scars in the heart’s tissue
impairing its normal functioning of muscular contraction.
• Chronic high blood pressure (hypertension).
• Heart valve insufficiency.
• Cardiomyopathy: primary disease of the heart muscle itself,
such as:
– Dilated cardiomyopathy: growth of the ventricle with-
out an increment of its wall-musculature and with a
decrease of the ejection fraction.
– Hypertrophic cardiomyopathy: progressive thickening
of the heart musculature with an abnormal alignment
of muscle cells.
– Restrictive cardiomyopathy: myocardial disease charac-
terised by restrictive filling and reduced diastolic volume
of either one or both ventricles with normal or near-
normal systolic function and wall thickness.
• Congenital heart defects: heart defects present at birth.
8
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• Endocarditis and/or myocarditis: infection of the heart valves
and/or heart muscle itself.
(Association, 2006), (Richardson P, 1996)
2.1.2 Therapies
Surgical procedures, such as heart valve replacement and bypass
operations, as well as medication treatment, such as beta blockers
and ACE inhibitors are established therapies to treat CHF. Both
medications have primarily a blood pressure-lowering effect.
When the above mentioned therapies are unsuccessful, the heart
of the patient will deteriorate to class IV and only a heart trans-
plantation is left as a solution. Alas, the number of candidates
far exceeds the number of available donor hearts. This has been
the initial reason to develop artificial hearts. They can serve as
a bridge to transplant by supporting or substituting the failing
natural heart. They can be classified into two groups:
1. VAD: support of the left, right or both ventricles.
2. TAH: replacement of the natural heart.
As experience has gained and technology has advanced, they
have demonstrated to be an effective alternative for different indi-
cations.
1. Bridge to recovery: support of the heart until it fully reco-
vers, for example after an open-heart surgery or cardiogenic
shock.
2. Bridge to transplant: support of the heart until a suitable
donor heart is available.
9
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3. Bridge to bridge: support of the heart until a more appro-
priate device is available.
4. Destination therapy: long term heart support.
Figure 2.2: Kaplan-Meier survival curve from REMATCH
trial. Optimal Medication Management (OMM) and Left Ven-
tricular Assist Device (LVAD) (Park SJ, 2005).
One of the most famous landmarks in scientific publications
within this field has been the REMATCH trial (Randomized Eva-
luation of Mechanical Assistance for the Treatment of Congestive
Heart Failure). This multicenter study was initiated in 1999 and
continued in the years after. It demonstrated that the survival
of patients with end-stage heart failure and not eligible for trans-
plantation is superior with implantation of left-ventricular assist
devices compared with any available medical therapy in patients
(Fig. 2.2) (Rose EA, 1999) (Park SJ, 2005).
Nevertheless, the clinical use of artificial hearts is still below ex-
pectation. Reasons are problems in regard to the durability of the
10
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device, the complexity of implantation and medical complications,
such as multi-organ failure, haemolysis and thrombogenicity. Also
high costs of the current systems and the adjunctive surgical proce-
dures impede VAD’s and TAH’s to be a commonly applied therapy
for the treatment of CHF.
2.2 Comparable systems on the clinical
market
Since 1950, VAD’s and TAH’s have been under development. An
overview of well-known blood pumps is given in figure 2.3.
Only devices comparable to the ACcor and the VERSUS presently
available on the market will be presented in detail: NovaCor,
Heartmate XVE, ARROW Lionheart and AbioCor. For all other
blood pumps, the reader is referred to the literature.
2.2.1 NovaCor
(Edwards Lifescience / Worldheart, Ottawa, Canada)
The Novacor is a left ventricular assist system with an electro-
magnetic driven pusher plate principle (Fig. 2.4). The pump unit
contains a polyurethane pump chamber, which is periodically being
sandwiched by two pusher plates. The pusher plates are coupled
to a spring-decoupled pulsed-solenoid energy converter. When an
electric current is supplied to the energy converter, a magnetic field
forces the pusher plates to sandwich the pump chamber, which re-
sults in the blood flow into the aorta. After the electric current
has been switched off, two springs force the pusher plates to move
away from the pump chamber, allowing the blood inflow.
11
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Figure 2.3: Overview of well known-blood pumps being deve-
loped or available on the market.
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Figure 2.4: (a) NovaCor-pump unit: top dual pusher plate
and magnetic actuator can be recognised, (b) schematic illus-
tration of functional principle of NovaCor-System
The Novacor system serves as a bridge to transplant or as desti-
nation therapy. It is implanted within the abdominal wall. Rein-
forced inflow - and outflow conduits penetrate the diaphragm and
connect the pump with the left ventricular apex and aorta. The
Novacor system has been implanted in more than 1700 patients
since 1984 (Wheeldon DR, 2002), (Worldheart).
2.2.2 Heartmate XVE
Thoratec Corporation, Pleasanton, CA, USA
The Heartmate Vented Electric (XVE) is a left ventricular assist
system with an electromechanical pusher plate actuator (Fig. 2.5).
The pump unit of the Heartmate comprises a blood chamber and
an electromechanical driver, separated from each other by a flexible
diaphragm. The electromechanical driver consists of a low speed
torque motor, that drives a pusher plate through a pair of helical
cams. As the torque motor rotates, two diametrically opposed ball
bearings bear against the helical face cams attached to the pusher
13
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Figure 2.5: (a) Heartmate pump unit, (b) schematic illus-
tration of functional principle of Heartmate XVE: (I) end-
diastolic phase, (II) systolic phase, (III) diastolic phase, (1)
blood chamber, (2) diaphragm, (3) electromechanical driver.
plate. In this way the rotary movement of the motor is converted
into a linear motion of the pusher plate (Fig. 2.5). One motor cycle
corresponds to one pump ejection cycle. The motor is connected
to the external control unit through transcutaneous electric wires.
A special characteristic of the pump is the textured surface for
both the titanium casing as well as the flexible polyurethane dia-
phragm. It mimics the inside of blood vessels and helps preventing
the formation of blood clots inside the device.
The HeartMate system has been designed for bridge to trans-
plant as well as for destination therapy. It received FDA approval
in 1998 and has been used in over more than 1300 patients (Dow-
ling RD, 2004b), (Thoratec).
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2.2.3 Lionheart
ARROW International Inc., Reading, PA, USA
Figure 2.6: (a) Lionheart pump unit, (b) schematic illustration
of Lionheart pump unit: (1) rotor and roller screw, (2) stator,
(3) pump chamber, (4) pusher plate.
The ARROW Lionheart is a left ventricular assist system with
an electromechanical pusher plate actuator. A titanium case en-
closes the blood pump components including blood sac, motor and
inlet/outlet valves. The pump is driven by a brushless, direct cur-
rent motor, that actuates a roller screw with an attached pusher
plate (Fig. 2.6). Periodically reversing the motor current results in
a reciprocating linear motion of the screw. The blood sac is then
sandwiched between the pusher plate and the case in cycles. No
bond exists between the pusher plate and blood sac to ensure a
passive filling of the pump during diastole. Two mechanical valves
maintain the required unidirectional flow.
Blood enters the pump via the inlet cannula, which is attached
to the left ventricular apex. During compression, the blood is being
expelled into the ascending aorta via the outlet cannula.
The Arrow Lionheart left ventricular assist device is designed
for destination therapy. It was implanted in 23 patients in Europe
15
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and in 10 patients in the U.S.A. from October 1999 till April 2004.
It received CE Marking on November 7, 2003. Unfortunately, cor-
porate financial decisions have discontinued the ongoing trials of
the Lionheart presently.
(Mehta SM, 2001), (El-Banayosy A, 2003), (ARROW Interna-
tional), (Mehta SM, 2006).
2.2.4 AbioCor
(AbioMed, Danvers, Massachusetts, USA)
Figure 2.7: AbioCor TAH: (a) complete pump unit with inlet
cuffs and outlet grafts, (b) schematic illustration of the gear of
AbioCor: (1) valve motor, (2) cylindrical valve, (3) impeller,
(4) impeller motor.
Abiocor is a fully implantable total artificial heart (Fig. 2.7) and
consists of two polyurethane pump chambers and an electrome-
chanical hydraulic energy converter. Inside the energy converter,
a miniature centrifugal pump rotates unidirectionally and pumps
silicon oil alternately towards the left and right blood pump dia-
phragms. The required reversal of the hydraulic silicon oil flow
16
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is achieved by a thin walled cylindrical valve, which is rotated
by a second motor. In systolic phase, the silicon oil pushes the
diaphragm into the pump chamber, expelling the blood into the
aorta (in case of the left pump chamber) or pulmonary artery (in
case of the right pump chamber). During diastolic phase, it forces
the diaphragm to move towards the middle of the energy converter,
sucking the blood into the pump chambers. Polyurethane trileaflet
valves ensure unidirectional flow of the blood.
The complete system also contains a motor controller and a
transcutaneous energy transmission system. The AbioCor TAH
has been designed for destination therapy. The first clinical im-
plantation was performed on August 21st, 2001. So far, fourteen
patients in the clinical trial have received the AbioCor and the
longest patient survival was 18 months (Dowling RD, 2004a). A
detailed description of these trials can be found in appendix A.
The AbioCor received FDA approval under the constriction of Hu-
manitarian Device Exemption (HDE) on September 5th 2006.
(Bhunia SK, 2004), (Dowling RD, 2000), (Dowling RD, 2001),
(Dowling RD, 2003)
2.3 Systems in development at the
Helmholtz Institute
The Helmholtz Institute Aachen (HIA) has a long tradition in
the development of bloodpumps. Several systems have reached
the market, such as the MEDOS/HIA-VAD (Reul, 1999), Delta-
stream (Goebel C, 2002) (MEDOS) and the Impella axial pumps
(Meyns B, 1998) (Impella). Two implantable electromechanical
displacement pumps are currently being developed: ACcor and
17
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VERSUS. Both will be described here.
2.3.1 Total Artificial Heart: ACcor
Figure 2.8: ACcor pump unit: (1) left pump chamber, (2)
right pump chamber, (3) electromechanical actuator.
ACcor is an implantable total artificial heart and consists of
two polyurethane pump chambers and an electromechanical energy
converter (Fig. 2.8). Four mechanical valves ensure unidirectional
blood flow.
The electromechanical actuator is a combination of three diffe-
rent types of basic gears (Fig. 2.9): a highly integrated reduction
gear increases the torque of the ETEL brushless DC motor by
decreasing the rotation speed, a planetary gear wheel system for
generating a hypocycloid motion and two pusher plate rods. The
pusher plate rods are connected to the pusher plates, which expel
the blood out of the pump chamber and are actuated in an al-
18
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Figure 2.9: The pump unit: (A) cross sectional view in dis-
placement axis plane. (B) cross sectional view perpendicular
to (A): (1) inlet valve, (2) beam spring, (3) pusher plate rod,
(4) pusher plate, (5) pump chamber, (6) diapraghm, (7) out-
let valve, (8) brushless DC motor, (9) reduction gear, (10)
hypocycloidic crank, (11) air vent, (12) atrial cuff, (13) hous-
ing, (14) electronic unit. (Kaufmann R, 1992)
ternating way. In this way the adaptation to the organ perfusion
demand can be achieved by controlling the rotational speed of the
motor. The displacements curves, generated by the gear mecha-
nism, permit a cardiac output similar to that of the natural heart
(sinusoidal form).
The ACcor is developed to serve as a temporary bridge to trans-
plant or as a permanent replacement of the natural heart. ACcor
is in the phase of laboratory tests.
The complete concept of the ACcor heart consists of more com-
ponents (Fig. 2.10): The pump unit is supplied with energy
through a transcutaneous energy transmission (TET) system. An
implanted buffer battery (Lithium Polymer) enables the patient
to take a shower without carrying extracorporeal equipment. The
compliance chamber compensates volume changes inside the elec-
19
2 Clinical and technical background
Figure 2.10: ACcor Concept: (1) ACcor, (2) compliance cham-
ber, (3) external batteries, (4) external controller, (5) TET
system (6) buffer battery and internal controller
tromechanical actuator to enable optimised passive filling of the
pump chambers with blood during pumping (Kaufmann R, 1993).
The external diagnostics control unit allows non invasive monitor-
ing of the functioning of the TAH.
ACcor and Abiocor are similar in size, volume, weight, stroke
volume, frequency and hydraulic performance (Tab. 2.2). An
advantage of ACcor is that it consumes only half of the energy
compared to AbioCor. But the most important aspect is the pas-
sive filling of the pump chambers with blood. The active suction of
AbioCor during the diastolic phase (up to -80mmHg) led to several
20
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System ACcor AbioCor
Volume (ml) 640 700
Height (mm) 115 120
Diameter (mm) 94 85
Width (mm) 104 105
Weight (grams) 770 800
Stroke volume (ml) 65 60
Frequency (BPM) 80-140 75-150
Hydraulic output (L/Min) 0-8 0-8
Energy consumption (W) 10 22
Filling of pump chambers passive active
Table 2.2: Characteristics of ACcor in comparison to AbioCor.
problems in the clinical trials. Strong medication was necessary to
reduce haemolysis. Secondly, special cages positioned at the inlets
to prevent atrial damage caused thrombolytic events (Dowling RD,
2001).
2.3.2 VEntricular Recovery SUpport System:
VERSUS
VERSUS is an implantable left ventricular assist device and con-
sists of an electromechanical actuator encapsulated into a titanium
housing and a Polyurethane (PUR) pump chamber (Fig. 2.11).
Two polyurethane valves ensure unidirectional blood flow.
The electromechanical actuator converts the unidirectional rota-
tion of the brushless DC motor into a reciprocating linear motion
of a pusher plate (Fig. 2.12). Firstly, one stage of planetary gears
and a reduction ratio gear increase the torque of the motor and
reduce the velocity of the motor. Secondly, a special gear Kauf-
mann - Förster (KaFör) converts the rotation of the gear wheels
into a translational motion of the pusher plate. It was worldwide
patented in 1997 (EP0991887, 1997), (US6354814, 1998).
21
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Figure 2.11: Pump unit
In several cases of bridge to transplant with an assist system,
patients recovered and have been weaned from cardiac support
without the need of a donor heart (Frazier OH, 1996), (Mueller J,
1997), (Nakatani T, 1998) and (Dalby MC, 2003). VERSUS is
being developed for this purpose: bridge to recovery. It can be
used also as a bridge to transplant, in case the heart does not
recover.
VERSUS is cannulated to the left atrium and aorta to support
Figure 2.12: VERSUS: (1) pump chamber, (2) KaFör gear,
(3) brushless DC Motor with planetary reduction gear.
22
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Figure 2.13: VERSUS-Concept: (1) external battery / driver,
(2) driving and vent cable, (3) electromechanical pump unit,
(4) outflow cannula, (5) ascending aorta, (6) inflow cannula,
(7) left atrium (Foerster, 2003).
the left ventricle (Fig. 2.13). The system is completed by an
external driver with integrated battery. The percutaneous lead
has two functions: energy supply and venting of the pump unit.
As the maximum implantation time of VERSUS will not exceed
12 months, the system does not contain a compliance chamber or
TET system. Therefore, the operation is less complex and costs
are reduced. VERSUS is in the phase of animal experiments.
The main advantage of VERSUS is the implantation within the
hemithorax, whereas conventional VAD systems on the market,
such as NovaCor, Heartmate XVE and Lionheart are implanted in
23
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System NovaCor Heartmate Lionheart VERSUS
Volume (ml) 950 1220 250 250
Length (mm) 165 ∅100 ∅69 117
Width (mm) 132 / / 76
Height (mm) 61 50 71 48
Weight (grams) 1000 1200 680 350
Stroke (ml) 70 83 63 38
Freq. (BPM) 30-150 50-120 60-125 80-140
Flow (L/Min) 2-12 0-10 0-8 2 - 3 5
E-cons. (W) 20 12 10-22 4
Filling art semi-active passive passive active
Table 2.3: Characteristics of VERSUS compared to conven-
tional VAD’s.
the abdomen and thus require two-cavity surgery (Foerster, 2003).
The small height of VERSUS is the most important feature to en-
able the intrathoracic implantation. Another aspect is that VER-
SUS is being developed to partially unload the natural heart (up to
50%), whereas NovaCor, Heartmate and Lionheart are being de-
veloped for full unloading. Therefore, the hydraulic performance
and power consumption of VERSUS are only half compared to the
other systems (Tab. 2.3). Furthermore, all conventional systems
are cannulated to the left ventricle, but VERSUS is cannulated
to the left atrium to prevent damage of the ventricle, that has to
recover.
2.4 Research and development of blood
pumps
Figure 2.14 illustrates a global overview of the complete develop-
ment process of VERSUS and ACcor and their state of the art.
In general, the development of a medical device has to meet
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Figure 2.14: Overview of development process of ACcor and
VERSUS and their state of the art
the clinical demands and requirements. Usually, specific clinical
indications are addressed which result in concrete medical speci-
fications, contributed by clinical cooperation partners. Another
important step is the determination of the market potential and
costs to achieve market approval. Further important aspects are
the expected quality of life of the patient and the social acceptance
of the device.
The development process for ACcor and VERSUS can be divided
into three phases:
Conceptual phase Firstly, all functional specifications are defined.
Then several concepts of the device are filed. Qualitative de-
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signs are submitted to laboratory tests to determine which
concept is the best. The most promising concept is designed
quantitatively and is submitted to extensive laboratory tes-
ting. The first successful animal experiment is a mayor step
towards the proof of concept.
Design phase The laboratory type is submitted to an iterative
process between validation experiments and redesigns. The
goal is to reach design freeze: the stage, which obviates the
need for further design alterations as it is assumed that the
current labtype will successfully fulfill all requirements for
the product.
Production set-up and approval phase After reaching design free-
ze, the entire supply, manufacturing and production process
of the device is set-up and fixed. Quality standards for com-
pany processes (e.g. DIN EN ISO 9001) ensure that all
processes are defined and controlled. The second step is
market approval. Laws and governmental institutions exist
for protection of patients. All device related processes must
comply to these laws to receive FDA approval (U.S.A.) or
CE Marking (Europe), after which the product can be sold.
ACcor has not been submitted yet to in-vivo validation, whereas
VERSUS supported the left ventricle of a calf during 10 days in one
experiment. The previous development of ACcor and VERSUS has
been described in PhD theses (Kaufmann, 1996), (Foerster, 2003)
respectively. The following chapters describe redesigns of ACcor
and VERSUS and the validation methods they were submitted to.
At the end of each chapter, the final results are presented.
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redesign
This chapter discusses the development of ACcor from the first
animal experiment till its current status. Each section discusses the
performed validation test, its results and the consequent changes
in the design of ACcor.
Figure 3.1: Chronological order of development ACcor.
The subsections are not ordered chronologically. They have been
arranged in laboratory tests, in-vivo studies and anatomical stu-
dies. Figure 3.1 shows which model was used for the validation
method. ACcor III is also referred to as MiniACcor. Assembly
drawings of ACcor are presented in appendix B.
3.1 In-vitro validation
Laboratory tests are performed outside a living (in-vivo studies) or
dead organism (in-mortem studies). They are commonly referred
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to as in-vitro tests. The most common are hydraulic tests, func-
tional tests, endurance tests, flow visualisation studies and blood
experiments.
3.1.1 Hydraulic tests
The main goal of hydraulic tests is to investigate the hydraulic
pump performance of the total artificial heart at different pump
rates under physiological or simulated pathological conditions. The-
se experiments are repeated after each significant design change to
determine the influence on the pumping performance.
Material and methods
For these hydraulic tests, a mock loop for pulsatile cardiovascu-
lar implants has been developed at the Helmholtz Institute Aachen
(Fig. 3.2), (Knierbein B, 1992).
The mock loop can simulate the hydraulic performance charac-
teristics of the systemic circulation as well as of the pulmonary
circulation. The cylinder on the left side represents the left or
right atrium. It is open to the atmosphere and the atrial pressure
is generated by the height of the water glycerin mixture inside the
cylinder. Through the left connector the mixture flows towards
the artificial heart and is pumped into the cylinder on the right
side. This cylinder is hermetically closed and represents the aorta
or pulmonary artery. The water-glycerin mixture flows through
the upper tube with integrated nozzle into the cylinder on the left
side. The nozzle generates the pressure representing the peripheral
systemic - or pulmonary resistance. Inside the right cylinder an
internal cylinder is placed, which can be adjusted experimentally,
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Figure 3.2: The compact Helmholtz mockloop (Knierbein B,
1992).
to vary the volume of compressible air. In this way the pressure
fluctuation, which exists in the aorta or pulmonary artery, can
be simulated. For the TAH research two of these mock loops are
combined to simulate the entire human body.
The test fluid is a mixture of water (60%) and glycerin (40%) to
achieve the same viscosity as from blood. The standard value is
3 6MPas, but in practice the viscosity of blood depends on gender,
age and health of the patient. The values for non-pathological
physiological pressures are 5mmHg for the left atrium, 2mmHg for
the right atrium, 120/80mmHg for the aorta, 25/0mmHg for the
pulmonary artery.
The MiniACcor (ACcor III) and the external control unit (VAD-
ER) were tested in mock loops to determine the hydraulic perfor-
29
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Figure 3.3: Laboratory set-up for hydraulic tests: (1) Mini-
ACcor, (2A) systemic mock loop, (2B) pulmonary mock loop,
(3) pressure measurement, (4) flow measurement, (5) motor
driver.
mance of the pump unit (Fig. 3.3). Transonic equipment (Ithaca,
NY, USA) was used for the flow measurement and PVB X-trans
transducers (Smiths Medical, Düsseldorf, Germany) for pressure
measurement. Data acquisition was performed with a laptop with
an integrated national instrument card (Austin, Texas, U.S.A.).
The DAQ software was programmed in Labview 7.0. The data
rate was set to 200 samples per second and the flow, current, mo-
tor speed and pressure signals were stored.
A protocol is run to determine the hydraulic characteristics of
each operation point of the artificial heart. The pump rates of AC-
cor lie in between 60 and 140 BPM. The hydraulic characteristics
are defined in steps of 20 BPM.
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Results and discussion
The hydraulic performance of MiniACcor under physiologic con-
ditions lies between the 4.5L/min and 7L/min at pump rates of
80-140 BPM (Fig. 3.4). Under these conditions, the energy con-
sumption remains below 10W.
Figure 3.4: Hydraulic performance of ACcor against non-
pathological physiological pressures: 5mmHg for the left
atrium, 2mmHg for the right atrium, 120/80mmHg for the
aorta, 25/0mmHg for the pulmonary artery.
The ejection fraction is the fraction of water-glycerin expelled
from the pump chamber during the systolic phase. It diminishes
at higher pump rates. The reason is that the pump chambers
are not completely filled in their diastolic phase (at 140BPM, the
duration of the diastolic phase is 0.21s). It has to be investigated
if a small negative filling pressure or larger inlet valves are desired
to improve the filling of the pump chambers.
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3.1.2 Compliance chamber studies
The performance of ACcor is affected by air volume and pressure
fluctuations inside the pump unit due to the required difference in
left - versus right output (bronchial shunt) and the operation of
the pump.
Figure 3.5: Schematic view of ACcor pump unit: (1) left pump
chamber, (2) housing, (3) right pump chamber, (4) tube to-
wards compliance chamber.
A compliance chamber is needed to alleviate this problem by
maintaining constant volume and pressure conditions within the
artificial heart. The compliance chamber is attached to the arti-
ficial heart housing via a cannula (Fig. 3.5). It allows a passive
filling of the pump chamber and continuous operation of the system
once it is implanted.
There is also an access port attached to the compliance chamber
that is needed for applying additional air to the system because
over time air will dissipate through the biocompatible material
into the body, because of the negative pressures inside the thorax.
This can lead to a motor stop, because it has to overcome a large
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negative pressure inside the housing to expel the blood from the
pump chamber.
The requirements for the compliance chamber were determined
in laboratory tests. After collection of the data, it will be analysed
and used for the design specifications for the compliance chamber.
Material and methods
The same laboratory setup as illustrated in figure 3.3 was used.
The pump housing was connected to the atmosphere through a
PVC tube. It has an inner diameter of 10mm and is 40cm long. An
airflow sensor (FCO14-Micromanometer) was connected to the end
of this tube to measure the maximum airflow velocity when open
to the atmosphere. At each operation point, the end of the PVC
tube was temporarily connected to an air volume-measuring device
(U shaped tube with water) to determine the maximal air volume
displacement and maximum pressure inside the tube when closed
to the atmosphere. The in- and outlet pressures of the mock loops
were set to normal physiological pressures (aorta: 120/80mmHg,
pulmonary artery: 25/0mmHg, left atrium: 5mmHg, right atrium:
2mmHg). Four working points were defined: 80, 100, 120 and 140
BPM. Data acquisition was performed with a laptop with an inte-
grated national instrument card. The DAQ software was written in
Labview 7.0 and the data rate was set to 200 samples per second.
Results and discussion
The future compliance chamber will have to compensate a max-
imum air volume displacement of 24ml and a pressure of 27mmHg
(Tab. 3.1). The available space for the implantation of the com-
pliance chamber will have to be determined in anatomical studies.
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Pumprate Output vairmax Vairmax Pmax
80BPM 4.5l/min 192ml/s 21ml 21mmHg
100BPM 5.6l/min 247ml/s 24ml 19.5mmHg
120BPM 6.5l/min 289ml/s 22ml 26 4mmHg
140BPM 7.0l/min 528ml/s 20ml 27.3mmHg
Table 3.1: Results of compliance studies.
Another functional specification for the future compliance chamber
results from the conclusions of the hydraulic tests (section 3.1.1):
it could be used to generate a small negative pressure inside the
housing of ACcor to improve the filling of the pump chambers.
3.1.3 Flow visualisation studies
Blood flow through pump chambers is investigated with flow vi-
sualisation studies. The goal of these experiments is to improve
the efficiency of pumping, to prevent regurgitation and dead water
areas. Latter two could lead to formation of thrombi, causing a
stroke after being expelled from the pump.
The pump chambers of MiniACcor were redesigned based upon
the specifications obtained from anatomical studies (section 3.3.
The in- and outlet arrangement, valves and dimensions were al-
tered. The new pump chambers contain Medtronic Hall valves
(mechanical one-leaflet valves) to minimise the height of the inlet
connectors to prevent compression of the atria.
The goal of this flow visualisation study is to determine the
optimal position of the Medtronic Hall valves to maintain best
circular washout flow and to prevent dead water areas.
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Material and methods
The pump chamber of ACcor IV is manufactured by thermo-
forming. The pump chamber wall is made of a 3mm thick PUR
sheet (Fig. 3.5). The diaphragms are made of 0.2mm thick PUR
sheets. The outside diameter is 84mm and the height is 22.4mm.
The stroke of the diaphragm / pusher plate is 18.2mm and the
stroke volume is 60.5ml. The pusher plate (Hydex 202) is embed-
ded between two flexible diaphragms to prevent high shear stresses
within the diaphragms. The inlet - and outlet valves are 27mm
and 25mm Medtronic Hall valves respectively. The opening angle
of the mono-disc Medtronic Hall valve is 75◦, therefore it deviates
the flow by 15◦ in axial direction.
Figure 3.6: Flow visualisation experiments. (A) Laboratory
setup: (1) software, (2) high speed camera, (3) mock loop, (4)
pump chamber. (B) pump chamber with amberlite particles.
The pump chamber is connected to a mock loop for simulation of
the cardiovascular pressures (Fig. 3.6). The mock loop, equipment
for flow and pressure measurement and the water-glycerin test fluid
are equal to those used for the hydraulic tests (section 3.1.1). The
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pusher plate is driven by a linear induction motor (Copley Motion
Systems LLC, UK). Control software was programmed in LabView
(National Instruments, Austin, Texas, U.S.A.) and the linear in-
duction motor is set to perform a sinusoidal motion. The stroke,
frequency and percentage of systolic duration can be set for each
test cycle (Tab. 3.2).
pin psys pdias Stroke Dur. systole Temp.
[mmHg] [mmHg] [mmHg] mm [%] ◦C
9 120 80 18.2 50 22
Table 3.2: Parameters of flow visualisation study.
The pusher plate was painted black to achieve best contrast.
The high-speed camera (Camera FastCam, Photron, U.S.A.) was
set to 3000 images per second. Amberlite IRA-900 RF particles
(Rohm and Hass France S.A., France) with a diameter of 500µm
were selected as tracer particles. They have the same density as
the test fluid (ρ=1,087kg/dm3) and good reflection characteristics.
Several assumptions were made: the fluid flow is not disturbed by
the particles, heat transfer to the particles and other interactions
with the particles are being neglected and they all have a spherical
shape.
Two positions of the inlet valves have been investigated: devi-
ation towards the inner part of the pump chamber (Fig. 3.7, A)
and secondly deviation of the flow towards the pump chamber wall
(Fig. 3.7, B). The flow through the pump chambers is investigated
at each standard operation point of pump speed: 80, 100, 130 and
150BPM.
Results and conclusion
No significant difference in hydraulic performance was observed
36
3.2 In-vivo validation
Figure 3.7: Flow through right pump chamber. (A) Flow de-
viation towards inner part of pump chamber. (B) Flow de-
viation towards pump chamber wall : (1) inlet valve opens,
outlet valve closes, (2) diastolic phase, (3) outlet valve opens,
inlet valve closes, (4) systolic phase.
between the two positions. However less circular washout flow was
observed when the Medtronic Hall valve deviated the flow towards
the pump chamber wall (Fig. 3.7). Also flow deviation towards
the inner part of the pump chamber led to less turbulence behind
the inlet valve. Therefore, opening of the valve towards the inner
part of the pump chamber is preferred.
3.2 In-vivo validation
In-vivo studies are validation experiments performed in living or-
ganisms. In this stage they are synonym for animal experiments.
They are divided into short-term (acute) and long-term animal
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(chronic) experiments.
Four acute animal experiments with ACcor have been performed
in 2000 and 2001. In acute experiments, the animal is anaes-
thetised and is sacrificed after the procedure. The main medical
goal of these experiments is to determine the implantation proce-
dure: the fitting of the device and its connection to the cardio-
vascular system. Also the anaesthesia and the list of necessary
surgical instruments is defined. The main technical goal is to as-
sess the functioning of the device under physiological conditions.
Haemolysis rates and thrombogenicity are less meaningful due to
the short duration.
Material and Methods
The second version of ACcor, as described in chapter 2.3.1, was
Figure 3.8: ACcor with outlet grafts (1,2) and cuffs (3,4).
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tested in each experiment. The dimensions of the electromecha-
nical displacement pump unit are 94mm in diameter, 103mm in
width and 115mm in height. Its overall volume is 640ml and the
pump unit weighs 700 grams. The actuator is encapsulated into a
biocompatible PUR housing. Two polyurethane pump chambers
complete the pump unit. Each has one inlet valve (Bjork Shiley,
27mm diameter) and one outlet valve (Bjork Shiley, 25mm diame-
ter). The range of cardiac output lies between the 0 and
8L/min. Two 22mm Dacron outlet grafts and two Polyester/PUR
inlet-cuffs are used to connect ACcor to the cardiovascular system
(Fig. 3.8).
Surgical technique and pump strategy
Pre-operative procedures: the animal is kept fasting (NPO: Nil
per Os) during 24 hours before the operation (water allowed). The
anaesthesia (Isoflurane) is induced with a mask. As a left thora-
cotomy will be performed for implantation, the animal is placed
on its right side on the operation table and intubated. The in-
halation anaesthesia (O2 - N2O + Isoflurane) is continued un-
til mechanical ventilation is started. A stomach tube is placed
and the rumen is drained. The neck and the thoracic wall are
shaved to obtain a clean operation field. Finadyne (2ml/50kg),
Albipen 15% (5ml) and Dexamethasone (10mgr) are injected as
anti-inflammatory drugs. A monitoring clip placed in the mouth
or ear of the animal measures the blood saturation. The opera-
tion areas are disinfected with iodine and the rest of the animal is
covered with sterile towels.
The left external jugular vein and carotid artery are dissected
and cannulated for administration of infusions, blood sampling,
39
3 ACcor: validation and redesign
Figure 3.9: Implantation of the ACcor pump unit in a calf
during an acute animal experiment.
pressure measurement and for connection of the heart lung ma-
chine. Left thoracotomy is performed and the fifth rib is removed
to obtain a larger operation field. After opening the pericardium,
the heart lung machine is connected and started.
The vena cava, left atrium, the pulmonary artery and aorta are
dissected and clamped, after which the ventricles of the natural
heart are explanted. The total artificial heart is inserted to deter-
mine the required lengths for the cuffs and grafts. Each inlet cuff
is cut to the appropriate size and then anastomosed to the left or
right atrium. The outlet grafts are anastomosed to the aorta or
pulmonary artery. Each suture is controlled on bleeding by placing
the clamp more distal from the vessels. Then a heparin bolus is
administered to prevent blood clotting. The total artificial heart
is implanted and connected to the cuffs and grafts (Fig. 3.9). Si-
multaneously, the pump chambers are primed and de-aired with a
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saline solution. A hand pump is connected to a vent tube, which
leads to inner side of the housing of the pump unit. By injecting air
into the housing, the pump chambers will eject some of the saline
solution and flow bubbles can easily be discovered and removed.
During this process the clamps are slowly removed. After comple-
tion of the de-aeration, ACcor starts pumping and will overtake
gradually the function of the heart lung machine step by step. For
flow control, the transonic flow probes are placed on the outflow
grafts. Each cable leaving the thorax (vent, tube with electric
leads and flow sensor) are cannulated separately through the skin
for better closure of the hole. These lines are carefully fixated on
the animals back. During closure of the thorax, the several layers
of the skin are sutured separately to prevent a pneumothorax.
The animal remains under anaesthesia during the whole test
period. The pump rate is increased from 80BPM to 120BPM in
steps of 20BPM. The stability and functionality of the device and
its influence on the cardiovascular system will be investigated.
The experiment is terminated normally after a few hours. The
thorax is opened and a heparin bolus is given to prevent post-
mortem clotting of blood. The anatomical position of the device
is controlled. After administration of an overdoses of anaesthesia,
ACcor is explanted and all blood contacting materials are investi-
gated on thrombi (pump chamber, cannulas, cuffs and grafts).
Because of the short duration of the experiment, the haemoly-
sis will not be measured and the organs are not investigated on
infarcts.
Results and conclusions
The four experiments with ACcor demonstrated the proof of
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Experiment Clinic OP-Date Duration Animal model
AC-AT 01 Vienna 21.06.1999 2 hours Calf, 123 kg
AC-AT 02 Vienna 29.05.2000 1 hour Calf, 111 kg
AC-AT 03 Aachen 05.03.2001 2 hours Calf, 214 kg
AC-AT 04 Aachen 22.05.2001 8.5 hours Calf, 150 kg
Table 3.3: Overview of performed acute animal experiments
with ACcor.
concept of ACcor (Tab. 3.3). The arterial and pulmonary arte-
rial pressures remained stable during the whole test period after
implantation. In average, ACcor produced a systolic pressure of
100mmHg and a diastolic pressure of 55mmHg at 120BPM. The
power consumption was approximately 13 watts. After explanta-
tion, the pump chambers were investigated macroscopically and
were free of thrombi.
Still, the animal experiments led to the following conclusions:
1. The anastomosis to the atria was difficult, because of the
little available space.
2. The bovine model should weigh at least 120kg, because con-
trary to the human thorax, the thorax of a calf is small in
the left-right direction and long in the sternal- vertebral di-
rection. A wide TAH cannot be placed against the sternum
and as a consequence would compress the atria impeding
the inflow. The width of the new TAH should therefore be
smaller.
3. De-airing the right pump chamber was difficult, because of
its occlusion by the actuator during bovine implantation.
4. Also in the new design, ACcor has to fill passively to pre-
vent high negative pressures during the diastolic phase, which
could damage the atrial walls.
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Design changes based upon in-vivo experience
Based upon the conclusions of the animal experiments, it was
decided to redesign the pump-unit. The main goals were size re-
duction of the pump unit (conclusions 1 and 2), separability (con-
clusions 1 and 3) and passive filling (conclusion 4). A lifetime of 2
years was set for this design. The basics of the gear mechanism of
the electromechanical actuator will not be altered as it proved to
be reliable, small and efficient. The main design changes will be
discussed now.
Size reduction of the pump unit.
The goal was to diminish the width and hence the volume of the
ACcor pump unit by 20% (conclusion 2). Three design changes
contributed to achieve this target:
• The stroke volume had to be at least 60ml. The stroke length
could be reduced by 2mm by improving the shape of the
stroke volume and geometry of the diaphragm.
• To achieve the required close arrangement of the in- and
outlets, the frame of the gear unit of the first ACcor was
designed in a triangular shape housing. This led to a wide
lower side of the TAH, which was disadvantageous for animal
implant (see pump unit in Fig. 3.9). The new housing was
designed in a cylindrical shape. The close arrangement of
the in- and outlets was achieved by the redesign of the pump
chambers.
• The balance between the left - and right output was originally
achieved by different diastolic times for the left and right
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Figure 3.10: (1) Internal geared wheel 1st stage, (2) Planetary
wheel 1st stage, (3) Magnets, (4) Motor housing, (5) Stator,
(6) Rotor, (7) Ball bearing, (8) Quarter rotary closure (1st
part), (9) Pin, (10) Quarter rotary closure (2nd part), (11)
Screw, (12) Bearing center, (13) Ball bearing, (14) Distance
ring, (15) Cage, (16) Right diaphragm, (17) Sun wheel 1st
stage, (18) Pin, (19) Ball bearing (20) Shim, (21) Sun wheel
2nd stage, (22) Ball bearing, (23) Pin, (24) Planetary wheel
2nd stage, (25) Ball bearing, (26) Ball bearing, (27) Shim,
(28) Ball bearing, (29) Pin, (30) Right pusher plate rod, (31)
Shim, (32) Right pusher plate, (33) Eccentric tappet, (34)
Reduction gear frame, (35) Ball bearing H, (36) Screw, (37)
Left pump chamber / snap closure, (38) Crank, (39) Housing,
(40) PUR Valve, (41) PUR snap lock, (42) Valve ring, (43)
Cuff ring, (44) Safety band, (45) Left diaphragm, (46) Artery
ring, (47) Cap nut, (48) Ring nut, (49) Shim, (50) Left pump
chamber, (51) Left pusher plate, (52) Left pusher plate rod,
(53)Internal geared wheel 2nd stage, (54) Distance ring, (55)
Seal ring valves (Not showed in picture).
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pump chamber. In the new design an eccentric tappet was
placed into the gear mechanism achieving a shorter stroke
for the right pump chamber (Fig. 3.10, Nr. 33). Currently
the stroke volumes are 60.6ml for the left pump chamber and
52.8ml for the right pump chamber.
• Miniaturisation of the gear components (gear wheels and
bearings) led to a smaller drive.
Separability
As the anastomosis to the atria was complex and the right pump
chamber was occluded during bovine implantation, it was decided
to make the pump unit separable (Fig. 3.11). This means that
first the left and the right pump chamber are inserted into the
thorax, then the in- and outlets are anastomosed to the atria, pul-
monary artery and aorta. The next step is to de-air the pump
chambers, which are now not occluded by the electromechanical
actuator. Finally the electromechanical actuator is being inserted
and attached to the two pump chambers. As the pump chambers
are manufactured from flexible polyurethane, it is possible to at-
tach the chambers directly upon the housing by a snap closure
(Fig. 3.10, Nr. 37). A safety band prevents the detachment of the
pump chambers.
Passive filling
To ensure passive filling the motion of the pusher plates were
made independent of the motion of the diaphragms of the pump
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Figure 3.11: Future implantation of ACcor: (a) cuffs and
grafts are anastomosed to atria, aorta and pulmonary artery;
(b) right pump chamber is connected and de-aired; (c) left
pump chamber is connected and de-aired; (d) electromechani-
cal actuator is implanted and attached to pump chambers.
chambers. The pusher plates received their own guidance dia-
phragms (Fig. 3.12). These diaphragms are perforated, allowing
airflow through the diaphragm. This means that in the end systolic
phase, the pusher plates and their guidance diaphragms will move
towards the middle of the electromechanical actuator, allowing air
to flow between the guidance - and pump chamber diaphragm en-
suring a passive filling. During the diastolic phase, the blood pres-
sure will press the air through the holes back towards the middle
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Figure 3.12: Schematic illustration of passive filling: (1) pump
chamber diaphragm, (2) pusher plate guidance diaphragm
with small perforations, (3) pump chamber wall, (4) housing.
of the electromechanical actuator. A separate compliance cham-
ber maintains the pressure and air volume inside the entire system
constant (section 3.1.2).
Changes of material
Several changes in material were made. All bearings obtained
ceramic balls to prolong lifetime without need of lubrication. To
save weight, the housing was manufactured of polyvinylchloride.
It has to be encapsulated with polyurethane to be biocompatible.
Also an outer ring of Hydex 202 was added to the pusher plates to
achieve a better bonding to the polyurethane guidance diaphragm.
Finite Element Methods (FEM) analysis of the ACcor
pusher plate
The pusher plates of ACcor are made of Polycarbonate. As
no experience had been obtained with this material so far, a FEM
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analysis was required to investigate if the pusher plate would with-
stand the existing forces. This analysis was performed in the FEM
section of the Computer Aided Design (CAD)/Computer Aided
Manufacturing (CAM) program I-DEAS (UGS, Plano, USA). Af-
ter importing the geometry of the pusher plate, the properties of
polycarbonate, such as the E-module and density, were filed.
The following boundary conditions were defined: (a) the pusher
plate is subjected to the pressure, that is exerted by the blood in
the pump chambers during functioning. A maximum pressure of
200mmHg is assumed and used as a load set on the surface of the
pusher plate. (b) on the surface, where the bearing is placed to
the piston rod as connection, all the rotations and displacements
are 0.
Figure 3.13: Results of FEM analysis: maximum stresses in
ACcor pusher plate (bottom view).
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The pusher plate was meshed and the calculation in I-DEAS
showed that the highest stresses exist at the surface, where the
bearing is placed (Fig. 3.13).
Results: the maximum tensile stress is 6.96 x 103 mN/mm2.
This is only 9.7% of the Yield stress. The maximum compressive
stress is 8.57 x 103 mN/mm2, which is 9.5 % of the compressive
strength. The maximum shear stress was 3.14 x 103 mN/mm2,
which is 2.8 % of the compressive strength. Therefore it can be
concluded that the pusher plate will withstand a static pressure of
200mmHg.
Failure analysis: the second investigation is how the pusher
plate will comport under series of loads (fatigue analysis). This
calculation gives an indication of the lifetime of the pusher plate.
First the variation of the load in time has to be defined: an oscilla-
tion between the 0mmHg and 200mmHg at a frequency of 140BPM
during two years lifetime. Then the failure index can be calculated.
If this value is larger than one, the pusher plate will break. If this
value is significantly smaller than one, then fatigue will not be
a problem. A failure index of 0.0818 was calculated. It can be
assumed that the lifetime of the pusher plate exceeds 2 years.
Main redesign results
The new design is approximately 18.5% smaller in width than
the old design. The diameter of the pump chamber remained 94mm
and that the width of the pump unit decreased from 104mm to
85mm. The pump unit weighs 470 grams and has a volume of
approximately 580ml. It is approximately 10% smaller in volume
than ACcor II (640ml). The inlets of the pump chambers are
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positioned on the lower lateral sides to prevent atrial compression
when implanted in a calf. As mentioned before the stroke volumes
for the left and right pump chambers are 60.6ml and 52.8ml, which
results in a baseline of the left - right balance of 14.7%. This value
may vary due to the passive filling of the pump chambers (section
3.1.1).
3.3 Anatomical studies
Anatomical studies in animal cadavers are performed to determine
the appropriate species, size and weight for animal experiments.
Anatomical studies in human cadavers are performed to define
the functional specifications for clinical use of the TAH:
1. Determination of the available implantation space for the
TAH and its components.
2. Investigation of the arrangement of in- and outlets of the
pump chambers, including the geometries of the cuffs and
grafts.
3. Preparation of the implantation protocol.
Three cadaver studies were performed with ACcor: one human
cadaver study and two animal cadaver studies.
Material and Methods
The human cadaver study was performed to verify the size of the
MiniACcor (ACcor III) in the human chest of small patients. The
study took place in the Heart- and Diabetes Centre North Rhine
Westphalia, Bad Oeynhausen, Germany. The patient (58 years,
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Figure 3.14: Anatomic study in human cadaver: (1) right ven-
tricle of Syncardia Cardiowest, (2) inlet cuffs and outlet grafts
of Syncardia Cardiowest: (A) pulmonary artery, (B) aorta,
(C) left atrium, (D) right atrium, (3) MiniACcor, (4) Dummy
of MiniACcor.
1.73m, 53kg) was diagnosed with dilative cardiomyopathy. He was
a candidate for transplant and received a Syncardia Cardiowest
(Tucson, U.S.A.) half a year before his death. The cause of death
was unknown. First the thorax of the cadaver was opened and
the position of the Syncardia Cardiowest TAH was investigated
(Fig. 3.14). After explantation of the TAH, the arrangement of
the inlet cuffs and outlet grafts were determined. In a third step
the MiniACcor was inserted into the cadaver and the feasibility
of implantation was investigated. In a next step, a dummy of the
MiniACcor with flexible outlets was used to define the possible
arrangement of in- and outlets. Finally a clay model was molded
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and used to determine the maximum allowed dimensions for im-
plantation.
Two anatomical studies in animal cadavers were performed to
determine the appropriate species for animal experiments, because
ACcor II compressed the atria partially and impeded the inflow in
the second animal experiment (AC-AT 02). The required weight
and size of the species were investigated also. The studies were per-
formed in the university hospital of Aachen. The first anatomical
study was performed in a sheep of 80kg (race: Merino). The se-
cond study was performed in a calf of 90kg (race: Holstein). Left
thoracotomy was performed and the native heart was explanted
and weighed. A dummy of the MiniACcor with flexible outlets
was inserted into the thorax to investigate the available implan-
tation space and compatibility with the arrangement of in- and
outlets.
Results and discussion
The MiniACcor fitted into the open thorax of the human pa-
tient. There was enough space available in the anterior posterior
distance (sternum to spine), which corresponds to the width of the
MiniACcor. The distance between the atria and the left side of the
thorax, which corresponds with the diameter of the pump cham-
bers was critical. The MiniACcor compressed the atria partially
after closure of the thorax. The clay model demonstrated that the
diameter of the pump chambers had to decrease from 94mm to
84mm for good fitting. The width of MiniACcor could increase
from 84mm to 94mm.
The inlets of the MiniACcor could be connected to the cuffs of
the Syncardia Cardiowest. But the inlet connectors will have to
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Figure 3.15: Results cadaver study: (A) front view of dummy
(B) top view of dummy. (1) left atrial inlet, (2) right atrial
inlet, (3) aortic outlet, (4) pulmonary arterial outlet, (5) driver
/vent tube.
be integrated into the circular part of the pump chambers as much
as possible to prevent compression of the atria. The connection
of the outlets to the aorta and pulmonary artery was possible,
because the grafts are long and flexible, but their arrangement have
to be changed to facilitate implantation. The most appropriate
arrangement of the outlets and the direction of the driver / vent
tube was determined with the flexible dummy and is illustrated in
figure 3.15.
The anatomical studies in the animals showed that the native
heart of the sheep weighed 305gram and that the heart of the calf
weighed 630gram. The diameters of the vessels were similar for
both animals. The aortic diameter was 22mm and pulmonary ar-
terial diameter was 25mm. More implantation space was available
in the calf. Contrary to the human thorax, the thorax of these
animals is small in the left-right direction and long in the sternal-
vertebral direction. Therefore, the most critical dimension of the
TAH for animal implantation is its width. The calf is preferred
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Nr. Requirement Quantification
1 Target group of patients
1.1 Body height 1.60m - 1.90m
1.2 Body weight 60 - 100 kg
2 Lifetime 5 years
3 Orthotopic pump unit
3.1 Diameter pump chamber 85mm
3.2 Width TAH 95mm
3.3 Total volume < 500ml
3.4 Total weight < 800g
3.5 Max flow rate up to 6 l/min
3.6 Flow rate at 120 bpm 5 l/min
3.7 Left-right balance ratio 1.00 - 1.10
3.8 Allowed pump frequency 90-150 BPM
4 Filling pressures -5mmHg > p > -20mmHg
5 Automatic adaptation No
to perfusion demands
Table 3.4: Updated functional specifications for ACcor
for future implantation, because more implantation space is avai-
lable at similar body size. Based upon in-vivo experience and the
cadaver study the calf will need to weigh 100kg to prevent atrial
compression when the MiniACcor is implanted. If the width of the
new ACcor increases to 95mm, as allowed for human implantation,
then a calf of 110kg is preferred.
Update of functional specifications
The anatomical studies led to an update of the primary func-
tional specifications of ACcor as described by Kaufmann et al.
(Kaufmann, 1996).
Requirements concerning the lifetime and hydraulic performance
were defined based on the clinical experience in Bad Oeynhausen
with implantable VAD and TAH systems (Tab. 3.4). Clinical ex-
perience in Bad Oeynhausen with the Syncardia Cardiowest TAH
in 100 patients demonstrated that a maximum flow rate of 6 L/min
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suffices. The difference between the left and right output was be-
tween the 0 and 10%. The Syncardia Cardiowest TAH is set to ne-
gative filling pressures between -10mmHg and -30mmHg to achieve
complete filling of the pump chambers. The lifetime of ACcor is
set to 5 years, because the main clinical indication is destination
therapy for patients, which are not eligible for heart transplanta-
tion.
Design changes based upon anatomical studies
The pump chambers of MiniACcor were redesigned based upon
the specifications obtained from anatomical studies. The diameter
of the pump chamber should not exceed 85mm and the stroke
volume has to be at least 60ml to provide sufficient output.
Figure 3.16: Design of diaphragm: (1) end-systolic position
pusher plate and diaphragm, (2) end-diastolic position pusher
plate and diaphragm, (3) pump chamber wall, (4) housing,
(D) diameter pump chamber, (S) stroke.
The design of the diaphragms is based on those of the pneumatic
MEDOS/HIA VAD (Knierbein B, 1992). The geometry of the dia-
phragm is designed in such a way, that the surface area maintains
constant at each stroke position (Fig. 3.16). Final values are a
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Figure 3.17: Pump chamber of ACcor IV: (1) inlet connector,
(2) outlet connector, (3) pusher plate.
19mm stroke and a 60.5ml stroke volume. The diameter of the
pump chamber is 85mm and its height is 22.4mm.
Medtronic Hall valves (mechanical one-leaflet valves) are inte-
grated to minimise the height of the inlet connectors to prevent
compression of the atria (Fig. 3.17). The diameter of the inlet
valves is 27mm and the diameter of the outlet valves is 25mm.
3.4 Improved system characteristics
A mayor step towards the proof of concept has been achieved in the
four acute animal experiments (section 3.1). ACcor II supported
the cardiovascular system for a total of 13.5 hours. The pump unit
was redesigned based on this in-vivo experience.
The redesign MiniACcor (ACcor III) measures 84mm in width.
The diameter of its pump chambers is 94mm. The pump unit
has a volume of 580ml and weighs approximately 470 grams (Tab.
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System ACcor II ACcor III ACcor IV
Volume (ml) 640 580 < 500
Height (mm) 115 115 < 90
Diameter (mm) 94 94 < 85
Width (mm) 104 84 < 95
Weight (grams) 770 470 < 800
Stroke volume (ml) 65 60.6 60.5
Frequency (BPM) 80-140 80-150 90-150
Hydraulic output (L/Min) 0-8 0-7 0-6
Energy consumption (W) 10 10 < 22W
Filling of pump chambers passive passive semi-passive
Table 3.5: Characteristics of ACcor II, MiniACcor and ACcor
IV.
3.5). The stroke volumes for the left and right pump chambers are
60.6ml and 52.8ml respectively. This results in a baseline of the left
- right balance of 14.7% and has been achieved by integrating an
excentric tappet into the gear mechanism. To prevent atrial com-
pression, the inlets of the pump chambers have been positioned on
the lower lateral sides of the pump chamber. The pump chambers
can be separated of the electromechanical actuator for an easier
implantation.
Hydraulic tests were performed with the MiniACcor (section
3.3). It pumps between 4.5 to 7 l/min against physiological pres-
sures at pump rates from 80 to 140BPM. Its power consumption
did not exceed 10W.
The requirements for the compliance chamber were determined
in compliance studies (section 3.1.2). The compliance chamber
needs to compensate a maximum air volume displacement of 24ml
and a maximum pressure of 27mmHg to allow passive filling of the
pump chambers during functioning.
Anatomical studies in animal cadavers demonstrated that the
calf is the most appropriate animal model for animal experiments,
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Figure 3.18: MiniACcor (ACcor III): pump unit with (1)
left pump chamber, (2) electromechanical actuator, (3) right
pump chamber.
because of the large implantation space available. The calf has to
weigh at least 100kg (section 3.3).
Anatomical studies in human cadavers and experience with the
SynCardia Cardiowest in Bad Oeynhausen led to new functional
specifications for ACcor (section 3.3). The dimensions of the pump
unit will have to be altered to enable implantation in smaller pa-
tients. The goal lifetime is set to five years, because the main
clinical indication has shifted to destination therapy.
The pump chambers were redesigned based on the new func-
tional specifications (section 3.3). Medtronic Hall 25 and 27mm
valves are used as in- and outlet valves respectively to minimise
the height of the in- and outlets. Flow visualisation studies demon-
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strated that the best washout of the pump chambers is achieved
when the inlet valves deviate the flow towards the inner part of
the pump chambers (section 3.1.3).
It can be concluded that the electromechanical MiniACcor is
a small and light total artificial heart with very low energy con-
sumption compared to AbioCor (section 2.2.4) It will provoke no
damage to the atria, because of its passive filling. Enough space is
available to adapt the gear mechanism to the new required dimen-
sions of ACcor IV. After this redesign, animal experiments will be
the main focus.
3.5 Pinpointing deficiencies
Several aspects of ACcor need extra investigation to improve the
system substantially. The will be discussed now:
The ejection fraction of the pump chamber diminishes at higher
pump rates (section 3.1.1). The reason is that the pump cham-
ber is not completely filled in its diastolic phase. Experience with
systems available on the market shows that the hydraulic output
is even lower in animal experiments and clinical use than in labo-
ratory experience. A small negative pressure inside the actuator
could support the filling of the pump chambers. Then a higher
output is achieved. The negative pressure could be generated by
the external compliance chamber.
The second characteristic that requires investigation is the abi-
lity of the passive filling / excentric tappet mechanism to achieve
the required difference in left - and right ventricular output, caused
by the bronchial shunt (section 2.1). In the hydraulic tests the poor
filling of the pump chambers explains the difference between the
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theoretical value of 14.7% and the experimental value of 10%. Al-
though it is expected that the passive filling of the pump chambers
allows ACcor to adapt automatically, because it pumps the venous
back flow it receives, extensive laboratory test are recommended.
The most important point of deficiency is the many moving and
rotating components of the gear. Especially if a five year lifetime
for destination therapy is required. Systems on the market, such
as NovaCor, Heartmate, Lionheart and Abiocor, have very few
moving components (section 2.2). Reduction of these components,
wear tests or even new gear concepts will be crucial steps to success.
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4 VERSUS: validation and
redesign
This chapter discusses the development of VERSUS starting from
the first animal experiment till its current status. Each section
discusses a validation test, its results and the consequent changes
in the design of VERSUS.
Figure 4.1: Chronological order of development VERSUS.
The subsections are not ordered chronologically. They are arranged
after in-vitro and in-vivo studies. Figure 4.1 shows which model
was used for the validation method. Assembly drawings of VER-
SUS are presented in appendix C.
4.1 In-vitro validation
VERSUS was submitted to several laboratory tests: hydraulic
tests, functional tests and endurance tests. Latter two led to sig-
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nificant design changes.
4.1.1 Hydraulic tests
The main goal of hydraulic tests is to investigate the pumping per-
formance of the ventricular assist device at different pump rates un-
der different simulated physiological and pathological conditions.
VERSUS is connected to a mock loop that simulates the cardiovas-
cular system regarding the pressure and flow properties. Important
data are flow output, power consumption and pressure generation
of the pump. These experiments are repeated after significant de-
sign changes.
Material and methods
The mock loop, data acquisition equipment and test settings
are equal to those explained in section 3.1.1 and are illustrated for
VERSUS in figure 4.2. Only one mock loop is used, because VER-
SUS is a left ventricular assist device. The mock loop simulates the
hydraulic performance characteristics of the systemic circulation.
A protocol is run to determine the hydraulic characteristics of
each operation point of VERSUS V. The pump rates of VERSUS
lie between 80 and 150BPM.
Results and discussion
The hydraulic performance of VERSUS V under physiologic con-
ditions lies between the 2.2 and 4.0L/min at pump rates of 80 and
150BPM (Fig. 4.3). The energy consumption is below 3.5W under
these conditions.
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Figure 4.2: Laboratory set-up for investigation of hydraulic
properties of VERSUS: (1) VERSUS, (2) mock loop, (3) pres-
sure measurement, (4) flow measurement, (5) motor driver.
The ejection fraction of VERSUS remains relatively constant
(70% at all operation points), because the filling of the pump cham-
ber is active and is therefore completely filled in the diastolic phase.
No damage to the atrium in clinical application is expected, be-
cause VERSUS will only assist the heart for 50%.
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Figure 4.3: Hydraulic performance of VERSUS V against
normal physiological pressures: 5mmHg for the left atrium,
120/80mmHg for the aorta.
4.1.2 Functional tests
The hydraulic performance of VERSUS was low in the first three
animal experiments (section 4.2). It varied between 1.0 and
1.3L/min. Several possible causes, such as suction, kinked cannulas
or negative filling pressures were simulated in laboratory tests to
investigate their influence on the hydraulic performance and pump
stability of VERSUS.
Material and methods
The hydraulic performance of VERSUS is investigated under
variation of three parameters:
1. Different sizes of outlet cannula: the first outlet cannula has
an inner diameter of 9.5mm and an outer diameter of 12mm.
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The second outlet cannula has an inner diameter of 16mm
and an outer diameter of 20mm. The length for both cannu-
las is 150mm.
2. Different sizes of inlet cannulas: MEDOS atrial cannula 32F,
40F and 50F (2.9French = 1mm). Their length was reduced
to 150mm according to in-vivo experience.
3. Different filling pressures (5, 0, -5, -10 and -15mmHg) to
simulate the in-vivo situation. The implanted position of
VERSUS high above the left atrium causes negative filling
pressures (Fig. 4.11).
The pump stability of VERSUS in case of suction is investigated
by an approximate 90% blockage of the inlet during three seconds.
The same laboratory setup as illustrated in figure 4.2 was used.
The pump rate is set to 100BPM and the pressures to normal phy-
siological values: 5mmHg for the atrial pressure and 120/80mmHg
for the aortic pressure.
Results
The inner diameter of the outlet cannula and the different fill-
ing pressures have little influence on the hydraulic performance of
VERSUS (<3.7%) (Tab. 4.1).
The inner diameter of the inlet cannula has large influence on
the hydraulic performance (>60%). The normal hydraulic perfor-
mance (Fig. 4.3) was achieved only when the 50F cannula was
used. Investigation of the cannula showed that the inner diameter
of the MEDOS atrial cannula varies and is smaller in the middle.
Therefore, VERSUS must generate very high suction pressures to
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Pinlet ∅ Inlet cannula ∅ Outlet cannula Output
5mmHg 32F 16mm 0.8L/min
5mmHg 40F 16mm 1.5L/min
5mmHg 50F 16mm 2.7L/min
5mmHg 50F 12mm 2.6L/min
0mmHg 50F 16mm 2.7L/min
-5mmHg 50F 16mm 2 7L/min
-10mmHg 50F 16mm 2.7L/min
-15mmHg 50F 16mm 2.7L/min
Table 4.1: Hydraulic performance of VERSUS under different
conditions
achieve complete filling of the pump chambers when the 32F and
40F atrial cannulas are connected. It was observed that when con-
nected to the 32 and 40F cannula, the diaphragm does not reach
its end-diastolic position. Therefore, the pump chamber does not
fill completely and only low output is achieved.
Figure 4.4: (A) Normal functioning of rocker/fixture mecha-
nism, (B) malfunction: (1) rocker, (2) coupler, (3) fixture
The 90% blockage of the inlet during three seconds led two times
to a rupture of the crank gear and two times to small ruptures in
the diaphragm. The crank gear is driven by the fixture and enables
a straight-line motion of the pusher plate, which is attached to the
coupler (Foerster, 2003). The location of this gear within the pump
unit can be found in appendix C. The force generated by suction
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forced the rocker to remain in its end systolic position (Fig. 4.4).
As a consequence, the fixture rotated first towards its end diastolic
position causing damage to the swash bolt and rocker. The small
ruptures in the diaphragm appeared in two regions: the transition
from the pusher plate to the diaphragm and the transition from
the diaphragm to the pump chamber wall.
Design changes based upon functional tests
The design changes to improve the hydraulic performance and
the stability will be discussed now.
Based upon the results (Tab. 4.1), the 50F MEDOS atrial can-
nula and the 16mm JOTEC Flownit graft are chosen as connections
for future animal experiments.
Rocker block
Figure 4.5: Normal functioning of rocker/fixture mechanism:
(1) enlarged rocker, (2) coupler, (3) fixture and (4) blocking
geometry.
67
4 VERSUS: validation and redesign
To prevent malfunction of the gear (Fig. 4.4), the rocker will
have a limited angle of rotation. This is achieved by adding an
extension to the rocker and a blocking geometry (Fig. 4.5). In this
configuration, the rocker will always be the first to rotate towards
its end-diastolic position.
Embedded pusher plate
Figure 4.6: Pusher plate / diaphragm configuration. (A) For-
mer configuration: (1) pusher plate, (2) single diaphragm, (a)
region with high shear stress. (B) New configuration: (1)
pusher plate, (2) upper diaphragm and (3) lower diaphragm.
The ruptures in the diaphragms were caused by the shear stresses
in the transition from the pusher plate to the diaphragm, that
occurred in the active filling phase (region a, Fig. 4.6). In the
new design the pusher plate is embedded between two diaphragms,
which are bonded to each other. They are subjected to tension
stress only: the upper diaphragm during the systolic phase and the
lower diaphragm during the diastolic phase. The manufacturing
process of the pump chambers was improved to prevent ruptures
in the transition from the diaphragm to the pump chamber wall:
the circularity tolerance of the pump chamber wall and diaphragm
was narrowed.
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Automatic adaptation to perfusion demand
As a third consequence, a first lab type of a control system to
avoid suction and to achieve automatic adaptation to perfusion de-
mand is developed. Perfusion demand is the required blood supply
to organs and is low at rest and high during physical activities. In
this way damage to the left atrium and the gear can be prevented.
Figure 4.7: Inlet connector with pressure sensor: (1) tube with
silicon oil, (2) PUR diaphragm and (3) inlet connector.
the control system is based upon the left atrial pressure, which is
measured in the inlet connector before the inlet valve (Finocchiaro,
2004). A pressure rise or fall within the left atrium is transmit-
ted via the 0.2mm PUR diaphragm and silicon oil to an external
pressure sensor (Fig. 4.7). Main advantages are that the blood
stream through the connector is not influenced and that the ex-
ternal pressure sensor can be calibrated on command to prevent
drifting of the value. The external pressure sensor is type SM5852-
008 manufactured by Silicon Microstructures Incorporated (Milpi-
tas, CA, U.S.A.). It transmits the data to a micro controller type
AN2131 (Cypress, San Jose, CA, U.S.A.), which is integrated into
the driver of VERSUS. In combination with a software algorithm
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(programmed in C++) the pump speed adapts accordingly.
Figure 4.8: Automatic adaptation of pump speed of VERSUS
to maintain constant atrial pressure: (A) simulated atrial pres-
sure increase, (B) simulated atrial pressure decrease.
VERSUS was tested in combination with the pressure sensor,
micro controller and algorithm software in in-vitro experiments.
The target value for atrial pressure was set to 4mmHg in the con-
trol software. The initial pump rate of VERSUS was 60BPM. Suc-
tion was simulated by changing the resistance of the inlet cannula.
As first step the resistance was lowered and the atrial pressure
increased to 6mmHg (Fig. 4.8). The control software responded
by increasing the pump rate of VERSUS until the atrial pressure
reached the target value. As second step the resistance was in-
creased, which led to an atrial pressure drop of 3mmHg. As re-
sponse, the pump speed of VERSUS was lowered. As future step,
the control software should be able to stop the pump function tem-
porarily when complete suction occurs.
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4.1.3 Endurance tests
The main goal of endurance tests is to determine the long term
stability of TAH or VAD systems. They are also referred to as
durability tests, fatigue tests or wear tests.
Several durability tests were performed with VERSUS. The first
series of durability tests focuses on the wear of two differently
treated swash bolts. It is the key component of the KaFör mecha-
nism and its rupture was the cause of termination of one animal
experiment after 11 days (VE-AT011, section 4.2). The diameter
of the swash bolt was increased from 3 to 5mm as a consequence.
The goal is to investigate which hardening treatment is best.
The second durability test was performed to investigate the sta-
bility of the complete pump unit and driver.
Material and methods
The laboratory set-up is equal to the set-up explained in section
4.1.1 (Fig. 4.2). All wear tests are performed under physiological
conditions: 5mmHg for the atrial pressure and 120/80mmHg for
the aortic pressure.
For investigation of the wear of the swash bolt, VERSUS was set
to 100BPM. The swash bolt is made of stainless steel (European
standard number 1.4571: American standard series (AISI): 316L).
Three different kinds of swash bolts were investigated (Fig. 4.9):
1. Swash bolt with diameter of 3mm (VERSUS IV): in-vivo
situation of VE-AT011, (section 4.2): untreated.
2. Swash bolt with diameter of 5mm (VERSUS V): plasma ni-
triding, depth: 0.3mm. Superficial Strengthening: 670 + 170
HV (Vickers Hardness).
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3. Swash bolt with diameter of 5mm (VERSUS V): low tem-
perature plasma nitriding, depth: 0,2mm.
After seven days the pump is stopped and the swash bolts are
investigated macroscopically.
The duration of the second endurance test to investigate the
wear of all components and the stability of VERSUS V was set to
20 days. The pump rate was increased every five days: from 80 to
140BPM in steps of 20BPM. In the last two an half hours the pump
rate is set to 160BPM. The temperature of the motor, hydraulic
performance and energy consumption were measured continuously.
The components of the gear were investigated macroscopically af-
ter termination.
Results and discussion
The bending angle of the untreated swash bolt altered from 55
degrees to 53 degrees and as a consequence it ground against the
swash plate and fixture. This was observed in the increase of power
consumption during the course of the experiment. The middle
part of the untreated swash bolt was extremely damaged after
seven days (Fig. 4.9). These results correspond to the in-vivo
experience. The swash bolt treated with high temperature plasma
nitriding showed almost no wear. This experiment lasted six days,
because the bearing within the fixture was broken. The third type
showed little wear at the positions of the bearings and this test
was stopped after seven days.
The second swash bolt seems the optimal solution, but there is
a complication with high temperature plasma nitriding: the exact
bend angle of the swash bolt after the treatment is hard to predict.
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Figure 4.9: Overview of swash bolts: (1) untreated, (2) plasma
nitriding, (3) low temperature plasma nitriding; (A) before the
experiment, (B) after seven days.
The high temperatures relief the stress and the swash bolt bends
back into its original straight shape. This leads to bad fitting into
the bearings. The swash bolt, treated by low temperature plasma
nitriding will be used for future animal experiments. Simultane-
ously, a reliable and predictable manufacturing process will have
to be investigated and set-up.
The second endurance test with VERSUS V with the 5mm swash
bolt, treated with low temperature plasma nitriding, reached the
planned 20 days without malfunction. The output varied between
2 2l/min at 80BPM and 3 6l/min at 140BPM (Fig. 4.10). The
energy consumption did not exceed 3 Watts and the temperature
of the motor remained below 36◦C. The last 2.5 hours, VERSUS
38◦C). Except for two slightly damaged teflon shims, the VERSUS
mechanism showed no wear.
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Figure 4.10: Measured data during the endurance test with
VERSUS. Illustrated are flow, energy consumption and the
temperature of the stator.
4.2 In-vivo validation
Fourteen animal experiments have been performed between 1999
and 2006. Two acute experiments were performed to define and op-
timise the implantation and anaesthesia protocol. The main goal
of the chronic experiments was to investigate the biocompatibi-
lity, haemocompatibility and pump stability of VERSUS in order
to improve the functioning of the device. Several times, design
changes and improvement in medical procedures were performed
before a new animal experiment was started. All animals received
human care in compliance with the "Guide for the Care and Use of
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Laboratory animals" published by the National Institute of Health
(NIH Publication no.85-23, revised 1985). The experiments were
approved by the ethical commission of the University of Nijmegen,
Netherlands (DEC-nr. 2004-045) and the district government of
Cologne, Germany (No. 50.203.2-AC 14, 06/02).
Material and methods
VERSUS is a small electromechanical displacement left ventri-
cular assist device with a polyurethane pump chamber and two
polyurethane valves (Foerster F, 2000), (Foerster F, 2001). Its
main characteristics are listed in table 2.3. Table 4.2 shows for
each experiment which version of VERSUS was used.
Surgical technique and anaesthesia procedures
All pre-operative procedures described in section 3.2 are per-
formed equally for the animal experiments with VERSUS. Inves-
tigation of the state of the natural heart (wall thickness, ejection
fraction) by echography is added to determine the therapeutical
effect of VERSUS (Aachen experiments only).
Then, the left external jugular vein and carotid artery are dis-
sected and cannulated for administration of infusions, blood sam-
pling and pressure measurement. Left thoracotomy is performed
(Fig. 4.12) and if little space was available, it was decided to re-
move a rib (usually the fifth). The pericardium is opened and Li-
docain as local anaesthesia is administered. A catheter is inserted
into the left atrium to register the pressure. The aorta descendens
adjacent to the left atrium is dissected and partially clamped with
a Satinsky clamp. Then the aorta is incised and end to side anas-
tomosis with the outflow graft is performed. The graft is de-aired
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Figure 4.11: Implanted position of VERSUS and cannulation
technique (left atrium - aorta descendens) in a bovine model
(Foerster, 2003)
with saline and closed on its distal part with a second clamp. The
Satinsky clamp is removed from the aorta and the anastomosis side
is controlled on bleeding. Then a Satinsky clamp is placed on the
left auricle of the atrium. The left auricle is incised and a short
graft is sutured to the left atrium. In a next step the inlet cannula
is positioned into the left atrium by inserting it through this graft
and then they are fixed to each other with a tie rib. This graft
stabilises the position of the inflow cannula in the atrium. At this
point, the cardiovascular system is prepared to connect the pump
and a heparin bolus is injected. The VERSUS including the in- and
outflow cannulas were primed and de-aired with a heparin saline
solution and then inserted into the thorax. The VERSUS pump
chamber is de-aired and the procedure is completed by connecting
the pump chamber connectors on the inlet cannula and then the
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Figure 4.12: Course of a chronic animal experiment of VER-
SUS: (1) left thoracotomy, (2) opening of pericardium, (3)
end to side anastomisis of outflow graft on aorta, (4) anas-
tomisis of short graft on atrium, (5) implantation of VER-
SUS, (6) position of inflow cannula, flow sensor and outflow
graft after connection, (7) aftercare facilities for calf, (8) ex-
plantation of pump unit.
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outflow graft. For flow control, a transonic flow probe is placed on
the outflow graft. The clamps are removed and the pumping of
VERSUS is started.
The ventilation of the animal is taken over by hand. The ca-
bles of the flow sensors, devices and pressure sensors are posi-
tioned through the skin separately to achieve a better closure of
the wound. These lines are carefully fixated on the animals back.
After closure of the thorax, the different layers of the skin are sewed
separately to prevent a pneumothorax. Finally the anaesthesia is
finished by reducing isoflurane concentration and by letting the
animal breath spontaneously. When the condition of the animal
is well, it will be positioned into its cage and transported into the
aftercare room.
The calf received intensive care during the first 24 hours after
the operation. The chance of bleeding is the largest in this period
and therefore the anticoagulant management is critical. Heparin
was administered to prevent thrombus formation and haemolysis.
The target value for the ACT was 200 seconds. Buprenorphine R©
was administered as analgesia and was given throughout the entire
duration.
Echocardiographic data (AT04-AT11)
Before and after implantation of VERSUS and before explan-
tation, thransthoracic echographic measurements were performed.
Two-dimensional measurements were performed to determine the
dimensions of the left ventricle and left atrium.
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Results: duration and termination causes
The first two animal experiments were acute bovine experiments
(VE-AT01 and 02) (Tab. 4.2). The first experiment was termi-
nated because of pump failure, whereas the second experiment was
successful.
The experiments VE-AT04 and 05 were performed in sheep,
because adult sheep will not grow during the experiment unlike
calves. This was considered to be an important factor, because
future testing would exceed several months. However, experience
showed that the lungs of the sheep were very vulnerable. The se-
cond sheep was in such a bad condition that the experiment had
to be terminated.
The total sum of implantation time of chronic animal experi-
ments in calves is 78 days, which means with n = 10 that the av-
erage duration was 7.8 days. Medical complications caused abrupt
ending of the experiment three times (VE-AT07, 13 and 14). De-
vice complications caused abrupt ending of the experiment five
times (VE-AT03, 08, 10, 11 and 12). Two experiments were termi-
nated selectively after achieving their maximum allowed duration
of seven days (VE-AT06 and 09). In Germany, the ethical commis-
sion gave permission for a maximum duration of seven days of the
animal experiment, if the calf would remain in a small cage with
few freedom of movement (VE-AT11 was performed after sepa-
rate approval of the district government of Cologne). Nadroparine
as coagulant was subcutaneously administrated in VE-AT14. He-
parin could not be given, because the administering cannula was
kinked. Since no previous experience with Nadroparine in calves
existed, the anticoagulation therapy was not optimal and the throm-
bus was formed at the valve position.
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In average, the output of VERSUS varied between 1.0l/min and
2.7l/min at pump rates of 80-120BPM. The power consumption
remained below 4 watts.
Hemodynamic findings
For all successful experiments (duration > 7 days; VE-AT03,
06, 09, 11 and 14), it was demonstrated that the arterial and pul-
monary arterial pressures remained stable during the whole test
period after VERSUS had been implanted.
Echocardiographic data (VE-AT04 - VE-AT11)
For all successful experiments performed in Aachen (VE-AT06,
09 and 11), the partial unloading of the heart by VERSUS led to a
slight decrease of the left ventricular end-diastolic (13%) and end-
systolic (12%) diameter as well as cardiac output (30%). This data
demonstrates that VERSUS is an effective support of the naturel
heart. The natural heart has to pump less blood and is allowed to
recover.
Evaluation of blood samples
The blood values showed a similar behaviour for all successful
experiments in Aachen: haemoglobin and the number of platelets
decreased peri-operatively due to surgical reasons (drop of 34% and
36%, respectively), but increased continuously thereafter. Except
for the first operative day (as a consequence of the operation), the
free haemoglobin did not significantly enhance in the postoperative
course (increase of only 4%) The function of peripheral organs
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(kidney, liver) was slightly impaired with a maximum value on
postoperative day 3 (increase of the creatinine and the bilirubin by
43 and 300%, respectively), but recovered within the test period.
Design changes based upon in-vivo experiences
Figure 4.13: Section view of VERSUS: (1) top housing, (2)
base plate, (3) rocker block, (4) rocker, (5) drive gear, (6)
swash plate, (7) fixture, (8) swash bolt , (9) pusher plate, (10)
intermediate gear, (11) pinion gear, (12) temperature sensor,
(13) middle housing, (14) motor, (15) pump chamber, (16)
diaphragm.
Each time, when an experiment had to be terminated due to
pump failure, the failing part was redesigned and improved. Also,
non-critical experiences led to design changes. The most significant
design changes are presented. The concerned parts within the gear
mechanism are shown in figure 4.13.
Temperature sensor
Two experiments had to be terminated due to a rupture of a
bearing. This rupture blocked the gear system and as the motor
still tried to rotate, all energy was converted into heat. In one
experiment necrosis of native tissue appeared, because of these
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Figure 4.14: Large arrow indicates necrosis of tissue after 10
days of implant, small arrow indicates position of new inte-
grated temperature sensor.
high motor temperatures (Fig. 4.14). In laboratory tests it was
demonstrated that the temperature of the stator could exceed the
100oC. A temperature sensor has been integrated and is located
inside the motor (Fig. 4.14). When the temperature exceeds 50oC
(which only occurs at system blockage) an alarm is issued. Note
that the temperature of the motor normally does not exceed 40oC
during animal experimentation and is not directly in contact to
the blood stream.
Pusher plate
In one animal experiment, the left atrium was temporarily poorly
filled with blood. The screws, which connect the coupler (Fig. 4.5,
Nr. 2) and the pusher plate, were torn out of the pusher plate
as a consequence of the active filling. The screw thread that was
directly cut in the polyurethane pusher plate was too weak. To
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Figure 4.15: Reinforced pusher plate: metal ring with screw
connection.
prevent similar failure, the screw thread is located in a metal ring,
which is bonded to the pusher plate (Fig. 4.15). Afterwards in ex-
tensive laboratory testing, in which the inlet was obstructed during
several seconds, no failure occurred. Also the problem was not en-
countered anymore in animal experiments.
Housing
The first housing was made of aluminium and enclosed by a
polyurethane sheet. The second housing of VERSUS was made
of titanium and designed in such a way that no screw was on
the outer side of the housing. During implantation, it was dis-
covered that the shape of the housing was not optimal as it was
too irregular and could damage the surrounding tissue. A new
housing was designed and manufactured of biocompatible Poly-
Ether-Ether-Ketone (PEEK) for weight reasons (Fig. 4.16). The
base plate however is still made of titanium for stability reasons,
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Figure 4.16: Former titanium housing of VERSUS III (above)
and the new smooth PEEK shaped housing of VERSUS IV
(below).
because it serves as the base for the entire driving mechanism.
Driver connector and venting tube
The diameter of the original driver connector was 18mm. This
led to two problems. First of all, it was difficult to pass the driver
cable between two ribs of a calf. Secondly a large cut had to
be made in the skin, which had to be closed afterwards around
the smaller venting tube. Therefore, a new connector with the
same outer diameter as the venting tube (approximately 12mm)
was selected and the design was changed. Also the length of the
driving tube was reduced to 75cm to achieve better exchange of air
between the atmosphere and the inside of the pump unit. Finally
a wire reinforced tube was chosen to prevent kinking of the driver
and venting tube (Fig. 4.17).
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Inlet cannula, outflow cannula and flowsensor
The output of the pump during in vivo experimentation was
only 40% compared to the pump performance in laboratory tests.
After additional verification laboratory tests (section 4.1.2), the
initial 40F atrial cannula (MEDOS AG, Stolberg) was changed to
a 50F atrial cannula. Secondly, the length of wire-reinforcement
was decreased to connect the pump closer to the natural heart.
After these changes, the difference in output during in vivo expe-
rimentation and laboratory tests decreased to approximately 25%,
which is caused by impaired filling conditions when connected to
the left atrium.
Figure 4.17: VERSUS with inlet cannula and outlet graft with
flow sensor.
As outflow cannula, first a combination of a polyurethane tube,
connector and graft was used. There were several disadvantages:
(1) a lot of transitions with formation of ring-shaped thrombi as
a consequence, (2) large length of the complete outflow assembly
(3) necessity of a large flowsensor, (4) connection of a non flexible
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polyurethane tube to the pump chamber.
In a first step, the design was improved by direct bonding of the
graft to the tube. Still, disadvantages (3) and (4) remained. In co-
operation with Transonic Systems new probes (16PAX) were tested
on 16mm diameter polyester grafts (FlowNit R© and FlowWeave R©,
JOTEC GmbH, Hechingen). After 24 hours the air dissolved out
of the graft and the flow could be measured.
VERSUS V in combination with the 50F MEDOS atrial cannula,
the 16mm Flownit graft and the 16PAX Transonic flow sensor is
the final configuration (Fig. 4.17). The number of transitions
has been minimised, the connection of the cannulas to the pump
chamber is facilitated and the desired length of both inlet - and
outlet cannula is very flexible.
4.3 Improved system characteristics
In-vivo experience and several laboratory tests have led to a large
improvement of the stability and implantation characteristics of
VERSUS.
Functional tests showed that VERSUS achieved the highest hy-
draulic output when combined with the 50F MEDOS atrial cannula
and a 16mm JOTEC Flownit outlet graft (section 4.1.2).
Suction was simulated also in functional tests by blocking the
inlet cannula temporarily (section 4.1.2). The blockage provoked
ruptures in the diaphragm and malfunction of the rocker mecha-
nism. This led to two design improvements: the pusher plate is
imbedded between a lower and upper diaphragm to prevent high
shear stresses within the diaphragms. A blocking mechanism to
limit the rotation of the rocker was added to prevent rupture of
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the gear.
Also, a first lab type of automatic adaptation to perfusion de-
mands to prevent damage to the left atrium and to the gear of
VERSUS was developed (section 4.1.2). A pressure sensor is in-
tegrated into the inlet connector. The pressure inside the inlet
connector corresponds to the atrial pressure. In combination with
control software, the pump speed is varied to maintain the pressure
constant. The system was successfully tested in mock loops, but
further development is required.
Several durability tests with VERSUS were performed (section
4.1.2). The first series of durability tests focused on the wear of
different treated swash bolts. The second series was performed to
investigate the stability of the complete pump unit and driver. The
first series led to the following improvements: the diameter of the
swash bolt increased from 3mm to 5mm and is treated now by low-
temperature plasma hardening. The second series demonstrated
stable performance of VERSUS V during 20 days: the output var-
ied between the 2.2l/min at 80BPM to 3.6l/min at 140BPM. The
energy consumption did not exceed 3 Watts and the temperature
of the motor remained below 36◦C. The hydraulic performance was
confirmed by hydraulic tests (section 4.1.1).
The proof of concept of VERSUS has been achieved in the animal
experiments. The chronic animal experiments with a total implan-
tation time of 78 days demonstrated good bio- and haemocompa-
tibility of VERSUS. The arterial and pulmonary arterial pressures
remained stable during the whole test period (section 4.2) and the
output varied between 1.0l/min and 2.7 l/min at pump rates of
80-120BPM. The energy consumption was below 4W.
Design improvements based on in-vivo experience, such as the
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System VE-III VE-IV VE-V
Volume (ml) 250 290 300
Length (mm) 117 128.5 128.5
Width (mm) 76 85 85
Height (mm) 48 48 50
Weight (grams) 350 475 550
Stroke volume (ml) 38 38 38
Frequency (BPM) 80-140 80-140 80-140
Hydraulic output (L/Min) 0-3.5 0-3.5 0-3.6
Energy consumption (W) 4 4 4
Max. implantation time (days) 10 11 37
Filling of pump chambers active active active
Housing titanium PEEK PEEK
Integrated temperature sensor no yes yes
Diameter swash bolt (mm) 3 3 5
Rocker blocking mechanism no no yes
Embedded pusher plate no no yes
Reinforced pusher plate no no yes
Diameter driver tube (mm) 18 18 12
Table 4.3: Characteristics of VERSUS III, IV and V.
reinforced pusher plate and the integration of a temperature sensor
led to increased stability and reliability of VERSUS. Other design
changes, such as the smaller driver and venting tube, the smooth
PEEK housing and the direct placement of the Transonic 16PAX
flow sensor on the JOTEC 16mm FlowNit graft led to easier han-
dling and implantation.
VERSUS V is larger in dimensions, volume and weight than
VERSUS III (Tab. 4.3). But with a volume below 300ml, it is
still in the same range as small continuous flow devices CorAide
(Doi K, 2004), (Fukamachi K, 2002) and VentrAssist (Watter-
son PA, 2000), (Esmore DS, 2005). The hydraulic performance
suffices for bridge to recovery and the energy consumption is ex-
tremely low (< 4W). Design changes led to a large improvement of
stability and reliability of VERSUS. The maximum implantation
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time increased from 10 days to 37 days. Based upon these results
it can be stated that VERSUS is a promising pulsatile ventricular
assist device.
4.4 Pinpointing deficiencies
VERSUS is being developed for bridge to recovery. It supports
the cardiovascular system by unloading the heart with 50%. VER-
SUS is designed to achieve a hydraulic output between 1.5 and
3.5l/min. However the market potential for destination therapy
and bridge to transplant is much larger, but these patients need
full unloading of the heart. VERSUS can be adapted easily to
achieve an hydraulic output of 5l/min. The brushless DC motor,
gear wheels and bearings are similar to those of ACcor and sustain
higher forces. The pump chamber must be enlarged to obtain a
stroke volume of approximately 50ml. This will lead to an increase
of volume, but VERSUS will remain still smaller than conventual
systems, such as NovaCor or Heartmate (section 2.3.2).
Another point of deficiency are the many moving and rotating
components of the gear. It is not as critical as with ACcor, because
the goal lifetime of VERSUS is one year. Reduction of these com-
ponents may be achieved by integration of a direct drive, so that
the system does not need the reduction gear. Also an alternative
solution for the rocker mechanism could lead to a large reduction
of moving components.
The wear of the swash bolt was investigated in durability tests
(section 4.1.3). The swash bolt, treated by the high temperature
plasma nitriding process, showed no wear after seven days. But the
exact bend angle of the swash bolt after the treatment is hard to
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predict, because of stress reliefs in the material during treatment.
A controlled manufacturing process must be set-up to enable the
use of the high temperature treated swash bolt for future clinical
indication.
Automatic adaptation to perfusion demands must be developed
to prevent damage to the left atrium and to the gear of VERSUS
(section 4.1.2). Suction is likely to happen occasionally, because
VERSUS achieves peak flows of 16l/min at 120BPM. The com-
bination of the pressure sensor with control software to vary the
pump speed was successfully testes in laboratory tests, but implies
integration of additional components. Therefore, less complex con-
cepts should be considered also.
Still, the results with VERSUS are promising enough to believe
that the system will support the left ventricle without malfunction
during one year. No haemolysis is provoked (Foerster, 2003), sta-
ble functioning in endurance tests has been demonstrated and the
haemocompatibility in animal experiments is good. As next step,
a series of long term animal experiments under equal conditions
will have to be performed to obtain more statistical data about
the reliability and haemocompatibility of VERSUS, after which
the project can be transferred to the industry.
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The animal experiments with VERSUS in Aachen (section 4.2)
were performed in the TOP project (Temporary Or Permanent
support). The TOP project was sponsored by the German Fede-
ral Ministry of Education and Research. The Aachen Centre of
Competence for Medical Technology was the managing entity of
the finances.
The TOP project comprised the development and validation
of several blood pumps, such as ACcor, VERSUS, Microdiago-
nal (Helmholtz Institute, Aachen, Germany), Impella RD, LD
(Abiomed, Aachen, Germany) and Deltastream (MEDOS, Stol-
berg, Germany). The main focus of the TOP project was the
in-vivo validation of these blood pumps in the University Hospi-
tal Aachen. An animal application was filed and approved by the
ethical commission of the district government of Cologne, Germany
(No. 50.203.2-AC 14, 06/02) in March 2002. The application com-
prised a total of 108 animal experiments.
The maximum duration of the experiments was set to forty days,
because initial medical complications, such as infections, are over-
come and the recovery of the animal should be complete. Also the
implanted device has proven to obtain good haemo- and biocom-
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patibility characteristics after forty days of uncomplicated implan-
tation. Long term durability of the blood pumps can be proven
separately in endurance tests (section 4.1.3).
The ethical commission approved the application under the re-
striction of complete freedom of movement of the animal seven
days after the operation. This chapter discusses the developments
steps that were performed to enable this freedom of movement and
their impact on time schedule and manpower.
5.1 Concept
The complete course of a chronic animal experiment was planned
and defined as follows:
1. Conditioning phase: an admission investigation of the animal
is performed after delivery. The animal will be treated in case
of disease, because only healthy animals are allowed to enter
the experiment. The last two weeks before the experiment
the animal is conditioned to the cage and contact to humans.
2. Operation: the blood pump is implanted and connected to
the cardiovascular system. Drivelines are led percutaneously
through the skin and connected through extension cables to
the motor driver electronics and Data Acquisition (DAQ)
equipment. The thorax is closed and the animal is trans-
ferred into a small cage.
3. Recovery period: the animal receives intensive care during
the first 24 hours after the operation. The animal has few
freedom of movement during this period (Fig. 4.12, nr. 7).
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The animal remains in this cage until it has recovered suffi-
ciently.
4. Chronic validation period: the animal has a large freedom
of movement. It is transferred to a larger cage. The pump
function has to be controlled continuously and the health of
the animal has to be controlled on a daily basis.
5. Termination: the blood pump is explanted after forty days
and investigated. The animal is sacrificed and its organs are
submitted to microscopic investigation.
Figure 5.1: Animal with complete liberty of movement.
Two options exist to achieve a large freedom of movement. A
swivel / tether mechanism allows the animal to turn around and
to move in each direction. The ethical commission approved this
option only if 24 hour observation was present, because the animal
could bite the cables. The second concept did not require 24 hour
observation and was chosen for this reason. A set-up which supplies
power to the pump by exchangeable batteries worn by the animal
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in a backpack in combination with fulltime telemetry-monitoring
of the pump function (Fig. 5.1).
Besides the development of the equipment and backpack, the
animal laboratory facilities also had to be adapted to fulfill the
European norms and will be discussed now.
5.2 Animal laboratory facilities
The laboratory facilities for the recovery - and chronic validation
period in the university hospital in Aachen was adapted to the
European norms and the requirements of the ethical commission
of Cologne. The rooms for conditioning, operation and termination
already complied to the norms and requirements.
Figure 5.2: Schematic illustration of animal room for chronic
validation period.
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The room for the chronic validation period was designed as fol-
lows (Fig. 5.2): two chronic test cages with water supply (cage 1
and cage 2) were installed and the entire floor was treated with
anti-slip wax. The transportable cage for the recovery period can
be placed within the same room, so that two experiments can be
performed at the same time and one person for surveillance suffices.
A cabinet with medicines and medical accessories was installed
as well as a cabinet with electronic equipment. Latter obtains
telephone and internet access, web camera, computer with data
acquisition software, spare batteries and battery chargers. The
web camera allows a 24 hours surveillance. However, the lights
in the room are switched of during the night and surveillance is
performed only by telemetry monitoring. Gas bottles and narcotics
are placed for thorax drainage and emergency operations.
The second development was the back pack (Fig. 5.3). The back
pack integrates the exchangeable batteries and electronics. The
back pack allows the body to sweat and breath, but also fits tightly
around the thorax to achieve stability. The material for the base
is HELIOSr body bandage (Schumacher, Krefeld, Germany) and
is also used in human clinical applications. The tail belt and collar
impede transversal movement of the back pack and the cushioned
box for the electronics impedes the rotation. The elastic lower
base comes in different sizes so that the back pack can be adapted
to each animal. The belts and hook and loop fasteners ensure
reliable bonding of the components. All belts are cushioned to
prevent striae. Quick release fasteners were selected for an easy
exchange of the batteries.
The back pack was also adapted to sheep. The back pack for
the ovine model does not have a tail belt and instead of a collar,
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Figure 5.3: (I) 3D CAD illustration of back pack: (1) telemetry
system and electronics, (2) base, (3) collar, (4) representation
of animal thorax, (5) exchangeable battery, (6) tail belt. (II)
2D drawings of back pack components: (A) lower base, (B)
upper base, (C) right battery, telemetry control / electronics,
left battery, (1) connection to collar belts, (2) connection to
tail belt.
three belts in an upsilon configuration provide additional fixation
(Fig. 5.4). Both back packs in combination with weight dummies
were tested in-vivo. They demonstrated good stability and were
accepted well by the animals.
5.3 Electro-technical equipment
The electro-technical equipment was developed in the same time
as the animal laboratory facilities and will be discussed now.
The flowchart in figure 5.5 represents an overview of the elec-
tronic equipment and their communication. It can be divided in
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Figure 5.4: In-vivo tests: (A) calf with back pack, (B) sheep
with back pack.
two groups: the equipment carried by the animal and the equip-
ment located in the cabinet.
The blood pump is implanted into the thoracic cavity of the
animal. Percutaneous cables connect the implanted blood pump
and the extracorporeal box. This box contains motor driving elec-
tronics, data acquisition boards and a telemetry system. The box
is located on top of the back of the animal and is on both sides
connected to an exchangeable battery (Fig. 5.3). A small puffer
battery, located inside the box, allows power supply for several
minutes during the exchange of the main batteries. The micro
controller is responsible for the communication between the vari-
ous components.
Pump data, such as power consumption, speed, temperature
and flow are collected by the micro controller and sent by the
telemetry system to the receiver in the cabinet. The receiver is
connected to a computer (DAQ system), that stores the data and
simultaneously sends the data through the internet to a back-up
system. A battery charger, an uninterruptable power supply (UPS)
and spare batteries complete the system.
The motor control electronics for ACcor and VERSUS were im-
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Figure 5.5: Flow chart of electronic components and data com-
munication.
proved and miniaturised (Fig. 5.6). For all three generations of
control electronics, the control of the brushless sensorless DC mo-
tor is based on back-Electro Motor Force (EMF) signals. The
first generation was developed by ETEL (Motiers, Switzerland)
and measures 200mm x 150mm x 150mm. The second genera-
tion was developed at the HIA and measures 110mm x 160mm
x 75mm. It contains a Kanda Development Kit ST7MTC2/EU
with a microcontroller ST72141 (Kanda Systems, Aberystwyth,
United Kingdom). The control software was programmed in as-
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Figure 5.6: Electronic equipment for ACcor and VERSUS: (A)
first - (left) and third generation motor control electronics, (B)
second generation motor control electronics, (C) batteries and
battery charger, (D) telemetry - and DAQ system.
sembly (Hartlief, 2002). The third generation was developed at
the HIA and measures only 90mm x 145mm x 45mm. It contains
a purchased Tsunami 10 controller (RCTmodel, Velserbroek, the
Netherlands). A volume reduction of 89% compared to the first
generation was achieved. Furthermore, the second and third gen-
eration allow continuous analogue data communication with the
telemetry system for data acquisition and pump speed control.
The battery packs deliver 28 volts and are designed for a conti-
nuous 28 hour functioning of ACcor so that only one change per
day is necessary during the experiment (Fig. 5.6). One nickel
metal hybrid battery contains 14 amp-hours, weighs 2.5kg and
measures 50mm x 240mm x 170mm. The battery is enclosed in an
aluminium housing for protection and its connection to the motor
control electronics is secured with a screw fixture.
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The flow sensor is connected to an OEM-board, which was deve-
loped by Transonic (Ithaca, NY, USA). The telemetry system and
the flow OEM board are integrated into one box, which was deve-
loped in cooperation with TeleMetronics Biometry (Almere, The
Netherlands). A blue-tooth protocol is used for the communication
with the receiver (frequency band 2.45GHz). The microcontroller
of the telemetry system was programmed and adapted for analogue
communication with the motor control electronics.
In the cabinet, a blue-tooth dongle serves as receiver and is con-
nected to a computer with the data acquisition software Porti-
lab (TMSI, Enschede, the Netherlands). The interface of Portilab
charts eight signals in real-time and alerts will pop up in case of
emergency (e.g. empty battery). The data is saved on the hard
disk and can be transferred to a back-up system through the in-
tranet or data storage medium.
The complete configuration was tested in a seven days labora-
tory experiment with the microdiagonal pump. The pump was
connected to a mock loop and set at 5800rpm. The pressure head
was set to 120mmHg, which resulted in a pump flow of 7l/min.
Each day the batteries were exchanged. Pump data, such as the
rotational speed, power consumption, flow and the voltage of the
exchangeable batteries were measured continuously at sample rates
of maximum 200/second. The motor driver electronics, telemetry
system and software Portilab showed stable function during the
entire test period. A daily back-up of the data was achieved with
a transportable data storage medium.
The animal experiments were not continued in Aachen after the
TOP project was stopped by the Aachen Centre of Competence
for Medical Technology in the same month when the laboratory
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test were performed.
5.3 Electro-technical equipment
Figure 5.7: Trolley for animal experiments: (A) camera, (B)
telemetry system and Transonic flow board, laptop with Porti-
lab, external hard disk, motor driver electronics, (C) uninter-
rupted power supply unit, camera server, pressure transducer,
(D) sterile supplies (flow probe, back-up system, e.g.).
System components, such as the camera, telemetry system, flow
measurement, motor control electronics and laptop with Portilab
were integrated into a transportable trolley (Fig. 5.7). This trolley
was used in animal experiments with VERSUS in Nijmegen (VE-
AT12 till VE-AT14) (section 4.2).
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5 Additional developments: wireless DAQ system
5.4 Impact on time schedule
The development to enable a large freedom of movement of the
animal has had an enormous impact on time and manpower during
the course of the TOP Project.
Figure 5.8: Overview on impact of time of each development.
It took two years and nine months from filing the animal appli-
cation till the adaptation of the laboratory facilities, completion of
the back pack and the development and laboratory validation of
the electro-technical equipment (Fig. 5.8). The complete set up
was ready for use in in June 2004. Thirty five animal experiments
with different blood pumps were performed simultaneously during
this period with a maximum duration of one week to obtain med-
ical experience. Manpower (two fulltime-equivalent) was shifted
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5.4 Impact on time schedule
from the Helmholtz Institute for these unexpected developments
and led to a considerate delay of the development of VERSUS and
ACcor. The project was stopped in June 2004 by the managing
entity Aachen Centre of Competence for Medical Technology due
to organisational and financial issues.
105

6 Systematic design and
validation of blood pumps
Blood pumps are being developed for different clinical indications.
The most common are cardiopulmonary bypass, dialysis, extracor-
poreal membrane oxygenation, ventricular assist or heart replace-
ment. Although the requirements for each indication are different,
there are similarities in the development of these blood pumps.
This chapter discusses a concept for the development process
of ACcor and VERSUS. It combines the experience of the valida-
tions and redesigns, discussed in chapter 3 and 4 with literature.
It demonstrates that the previously discussed validations and re-
designs are only a small part of the entire development.
6.1 Development process
The development of blood pumps is driven by clinical demands.
Market analysis, competitive analysis, development costs and the
required development time are important considerations in the
decision to start a new development or not. The development
process of a standard technical product (Lindemann, 2007) has
been adapted to the development of ACcor and VERSUS and is
illustrated in figure 6.1.
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Figure 6.1: (A) Schematic illustration of development process
of a technical product (Lindemann, 2007), (B) illustration
adapted to ACcor and VERSUS.
The development of ACcor and VERSUS can be divided into
five phases:
Development planning: the necessary development steps and re-
sources are being planned. Also the goal, structures and
functions of the device have to be clarified. As a result, the
functional specifications are determined and filed.
Conceptual phase: the main goal of this phase is to develop a
conceptual bench type that fulfills the main requirements of
the future device as stated in the functional specifications.
After achieving the proof of concept, the basic principle of
the conceptual bench type is usually not changed anymore
in further developments.
Design phase: this phase is an iterative process between extensive
validation experiments and redesigns to improve and deter-
mine the characteristics of the labtype. The main goal is
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to reach design freeze: the stage, which obviates the need
for further design alterations as it is assumed that the cur-
rent design will successfully fulfill all requirements for the
product.
Production set-up: the entire supply, manufacturing and produc-
tion process of the device is set-up and fixed.
Approval phase: the goal of this phase is to prove that each de-
vice, sold by the manufacturer, is reliable and therapeuti-
cally effective enough to be implanted into human-beings.
A governmental accredited institution (Notified Body) has
to control the compliance of the device to the Medical De-
vice Directives (93/42/EEC), (90/385/EEC) through audits
before CE Marking can be obtained.
The development of ACcor and VERSUS was started within the
research facility Helmholtz Institute Aachen. Experience at the
Helmholtz Institute demonstrates that a project is often trans-
ferred into the industry after successful validation of the blood
pump in a statistical series of animal experiments. The company
continues with the development of the device to reach design freeze,
after which the production is setup and the approval phase is en-
tered.
6.2 Conceptual - and design phase
This section presents the systematic development steps in the con-
ceptual - and design phase for implantable electromechanical dis-
placement blood pumps at the Helmholtz Institute. An overview
of corresponding design and validation methods is included.
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Figure 6.2: Systematic approach to the development and de-
sign of technical systems and products (VDI, 1993)
The VDI guideline 2221 has been used as a base model for the
development steps of ACcor and VERSUS (Fig. 6.2). It describes
a systematic approach to the development and design of technical
systems and products (VDI, 1993). The adapted version for ACcor
and VERSUS is illustrated in figure 6.3. The corresponding design
and validation methods are described and listed in table 6.1.
The development phases for ACcor and VERSUS with their cor-
responding design and validation methods are:
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Figure 6.3: Overview of conceptual - and design phase for
ACcor and VERSUS.
Product development planning: in case of ACcor and VERSUS,
the specific clinical indications were addressed and a project
plan was setup. The functional specifications were filed, in
which economical, clinical as well as technical requirements
were included. The concrete medical specifications were con-
tributed by clinical cooperation partners. Also, anatomical
studies were performed to define the available implantation
space and cannulation art.
Conceptual phase: several concepts for ACcor and VERSUS were
filed under the constriction of the main requirements. These
concepts were designed qualitatively and submitted to fea-
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sibility studies. The most promising concept was designed
more in detail as more requirements were taken into ac-
count. Then, a functional bench type was manufactured.
The used design methods were construction basics (litera-
ture) and CAD/CAM software. The conceptual bench type
was submitted to the following validation methods: hydraulic
tests, functional tests, blood experiments, short term dura-
bility tests (< 1 week) and pilot animal experiments. The
proof of concept was achieved after performing the first suc-
cessful animal experiment.
Design phase: the laboratory types of ACcor and VERSUS were
submitted to an iterative process of validations and redesigns
to improve or determine the characteristics of the blood pump.
Hydraulic tests, functional tests and blood experiments were
repeated. More time-intensive validation methods, such as
long term endurance tests, flow visualisation studies and long
term animal experiments were included also. Theoretical
analysis methods, such as FEM and Computational Fluid
Dynamics (CFD) were added to support the design process.
Experience at the Helmholtz Institute demonstrates that projects,
such as ACcor and VERSUS, are transferred usually into the in-
dustry before design freeze is reached. Note that although the
same design and validation methods may be used, the structure of
the development process is different in the industry. Quality man-
agement systems (DINENISO13485, 2003) and risk management
(DINENISO14971, 2000) play an important role.
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Validation method Purpose
Feasibility test Laboratory tests with conceptual bench
(Kaufmann, 1996) types to determine the most promising
concept
Hydraulic test Investigation of hydraulic performance un-
(section 3.1.1 and 4.1.1) der different simulated (patho-) physiolo-
gical conditions
Functional test Investigation of stability and functioning
(section 4.1.2) of blood pump under different simulated
conditions
Endurance test Middle - to long term investigation of wear
(section 4.1.3) and stability of blood pump
Flow visualisation study Investigation of blood flow through pump
(section 3.1.3) chambers and cannulas to determine exis-
tence of dead water areas and to improve
pumping efficiency
Blood experiment Investigation of haemolytic - and thrombi-
(Foerster, 2003) genetic characteristics of blood pump
Anatomical study Investigation of implanted anatomical po-
(section 3.3) sition, available space and cannulation art
Acute animal experiment Determination of implantation procedures,
(section 3.2 and 4.2) pump stability, hydraulic properties and
biocompatibility
Chronic animal experiment Investigation of pump stability, hydraulic
(section 4.2) properties, biocompatibility, haemocom-
patibility and therapeutical effectiveness
Design method Function
Construction basics Conceptual design, strength calculations
(Foerster, 2003) and durability analysis
CAD/CAM Creation of 3D models and 2D manufac-
(section 3.2 and 4.2) turing drawings. Generation of tool paths
for complex geometries
Manufacturing methods Design and material restrictions, manufac-
turing feasibility and costs
Finite element method Computer assisted analysis of pump com-
(section 3.2) ponents to predict the lifetime of device
Computational fluid dynamics Computer assisted calculation of blood
flow through pump chambers to predict
dead water areas and to improve pumping
efficiency
Table 6.1: Conceptual - and design phase: validation and de-
sign methods
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6.3 Production setup and market
approval
This section serves as a brief introduction of the production setup
and approval phase. It mainly demonstrates that the previously
discussed validations and redesigns are only a small part of the
entire development. The focus will be on relevant characteristics
for ACcor and VERSUS.
Production setup
In this phase, the complete production process of the blood
pump (from raw part to sterilised device) is defined, setup and
controlled. Risk analysis is an important step to determine risks
associated with manufacturing, sterilisation and transport. One
of the main goals of this phase is to deliver a high and constant
quality of the blood pump.
Production processes comply normally to the standards of qual-
ity management (laws). Well known standards of quality manage-
ment are (DINENISO9001, 2000) and (DINENISO13485, 2003).
They describe requirements and guidelines for:
• Manufacturing and quality assurance instructions: organi-
sation diagram of companies involved in the manufacturing
process. Flow chart and description of each manufacturing
procedure. Contractual agreements with suppliers and dis-
tributors.
• Standard operation procedures (SOP), Standard Working In-
structions (SWI): set of instructions to standardise opera-
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tions in order to achieve uniformity in the manufacturing
process.
• Packaging: design of packaging and specification of packaging
materials.
• Storage and transport: control of acceptable conditions, such
as temperature, humidity and mechanical impact.
• Labeling, instructions for use: layout and design of labeling,
warning labels, registration cards, device i.d. labeling and
manuals.
• Sterilisation: name and location of sterilisation company, de-
scription of sterilisation cycle.
An external govermental accredited Certification Body (CB)
controls the production processes through pre -, certification - and
surveillance audits (evaluations) to investigate if the production
processes comply to the standards. If so, the company can be-
come ISO9001 certified. After fixing the production process of the
medical device, the approval phase is entered.
Approval phase
The main goal of the approval phase is to proof that each device,
sold by the manufacturer is reliable and therapeutically effective
enough to be implanted into human-beings, who maintain an ac-
ceptable quality of life. The approval phase is controlled in Europe
by accredited Notified Bodies (NB), such as TÜV or KEMA. The
FDA is the responsible entity in the United States.
In Europe, medical devices must comply the requirements and
guidelines of the Medical Device Directive (MDD) (93/42/EEC)
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in order to reach market approval. Some important steps in the
approval phase are (TUEV-Rheinland, 2007):
Classification of medical device: medical devices are classified in
four different groups: class I (low risk), class IIa (medium
risk), class IIb (high risk) and class III (highest risk). ACcor
and VERSUS are active implantable medical devices (class
III) and are intended to be totally or partially introduced,
surgically or medically, into the human body or by medical
intervention into a natural orifice and which is intended to
remain after the procedure. Active implantable medical de-
vices must comply to the MDD (90/385/EEC).
Conformity assessment route: the manufacturer has to choose a
specific conformity route towards market approval. The choice
of route depends on whether the company is certified or not.
A Notified Body (NB) controls the conformity of the manu-
facturer (and device) to the MDD through a pre -, certifica-
tion - and surveillance audit at predetermined stages of the
route.
Risk analysis: the manufacturer must maintain a process for iden-
tifying hazards associated with the medical device, estima-
ting and evaluating the associated risks, controlling these
risks and monitoring the effectiveness of the control. For
example, he defines which validation methods must be per-
formed in order to achieve compliance to the MDD. Risk
analysis has its own international standard (DINENISO14971,
2000).
Series validation: performance of a series of validation tests to
which the medical device is subjected to. Common validation
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tests are:
• Determination of physical and mechanical properties:
tensile strength, temperature resistance, durability, etc.
• Chemical properties: compatibility with cleaning-, dis-
infection - and conservation agents.
• Electric properties: electrical safety and electromag-
netic safety.
• Biological compatibility: cytotoxity, systemic toxicity,
haemocompatibility, biodegradation.
• Packaging, storage and transport tests: protection against
contamination, loss of sterility, protection against me-
chanical impact.
• Sterilisation and bioburden tests.
• Animal tests and clinical trial.
Device Master File: required documentation for market approval:
• General description of the product
• Essential requirements of the device
• Design information: basic materials, characteristics of
the device, methods of manufacture and design dra-
wings.
• Descriptions and explanations necessary to understand
the operation of the device.
• Results of risk analysis.
• Description of the sterilisation procedures.
• Test reports.
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• Performance evaluation data showing the performances
claimed by the manufacturer and validation by a refe-
rence measurement system.
• Labels and instructions for use.
• Results of series validation.
Declaration of conformity: the manufacturer writes a declaration
of conformity in which he declares that the product intended
for the market meets the requirements of the MDD. The
declaration of conformity has legal value and any incorrect
claims are liable.
Certification by Notified Body (CE Mark): after receiving a writ-
ten confirmation (approval) from the NB in response to the
declaration of conformity, a manufacturer can affix the CE
mark on the product. The device and manufacturer will be
submitted to surveillance audits, in which they must present
their post-market vigilance and manufacturing processes con-
cerning the device.
Clinical experience after achieving market approval (CE Mark
for Europe and FDA approval for the United States) may lead
to necessary improvements of the device. These improvements
will have to be approved by the Notified Body before they can be
implemented in clinical use.
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The REMATCH trial demonstrated that mechanical circulatory
support is an effective alternative to optimal medication therapy
in the treatment of heart diseases (Rose EA, 1999). Blood pumps
are developed for different clinical indications, such as cardiopul-
monary bypass, extracorporeal membrane oxygenation, ventricular
assist (bridge to recovery, bridge to transplant, destination the-
rapy) or heart replacement. Although the requirements for each
indication are different, the development process for each blood
pump is similar. This PhD report has presented a strategy for the
development process. It combines literature and the experience
obtained from performed validation and redesigns steps with the
total artificial heart ACcor and ventricular assist device VERSUS,
currently under development at the Helmholtz Institute. ACcor
is being developed as bridge to transplant and destination the-
rapy (Kaufmann, 1996). VERSUS is being developed as bridge to
recovery and bridge to transplant (Foerster, 2003).
Validation and design steps with ACcor
Four acute animal experiments were performed with ACcor with
an accumulated cardiovascular support time of 13.5 hours. These
in-vivo experiences led to the proof of concept and recommen-
dations for a redesign. The new version MiniACcor (ACcor III)
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has a volume of 580ml, which is 18.5% smaller than its predeces-
sor. It weighs 470 grams and the two pump chambers can be im-
planted separately from the electromechanical actuator for easier
anastomises and de-aeration.
The MiniACcor was submitted to hydraulic tests and pumped
between 4.5 to 7l/min at pump rates from 80 to 140BPM against
physiological pressures. The maximum power consumption is 10W.
Compliance studies demonstrated that the compliance chamber
has to compensate a maximum air volume displacement of 24ml
and a maximum pressure difference of 27mmHg to allow passive
filling of the pump chambers.
Anatomical studies in animal cadavers demonstrated that a bovi-
ne model with a minimum weight of 100kg is appropriate for in-vivo
experiments. Anatomical studies in human cadavers and clinical
experience with SynCardia Cardiowest in Bad Oeynhausen led to
new functional specifications for the TAH. The diameter of the
pump chambers should decrease 10% to enable implantation in
smaller patients, but the width of the pump unit is allowed to in-
crease 9%. The lifetime of the TAH is set to five years, because
the main clinical indication has shifted to destination therapy.
The pump chambers were redesigned based on the results of the
anatomical studies. The stroke volume remained 60.5ml. Medtronic
Hall valves were integrated to minimise the height of the pump
chambers. Flow visualisation studies demonstrated that the best
washout of the pump chambers is achieved when the inlet valves
deviate the flow towards the inner part of the pump chambers.
ACcor is a small and light total artificial heart with very low
energy consumption compared to its competitor AbioCor. Unlike
its competitor, it will provoke less haemolysis as well as no damage
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to the atria, because the pump chambers are filled passively. A
series of animal experiments will be performed after adaptation of
the gear mechanism to the new dimensions to obtain statistical
values of the stability, durability, bio- and haemocompatibility.
Validation and design steps with VERSUS
In-vivo experience and several laboratory tests have led to a
large improvement of the stability and implantation characteristics
of VERSUS.
Functional tests determined that VERSUS in combination with
a 50F MEDOS atrial cannula and a 16mm JOTEC Flownit outlet
graft achieved the maximum hydraulic output. Simulation of suc-
tion provoked ruptures in the diaphragm and malfunction of the
rocker mechanism. In the new design, the pusher plate is imbed-
ded between a lower and upper diaphragm to prevent high shear
stresses within the diaphragms. Secondly, a blocking mechanism
that limits the rotation of the rocker was added to prevent mal-
function.
A first lab type of automatic adaptation to perfusion demands
to prevent damage to the left atrium and gear of VERSUS was
developed. A pressure sensor was integrated in the inlet connec-
tor of VERSUS and measures the pressure continuously. Control
software adapts the pump speed, so that a constant positive in-
let pressure is maintained and the atrium can not collapse. The
system was successfully tested in mock loops.
Based on durability tests, the diameter of the swash bolt was
increased to 5mm and is treated now by low-temperature plasma
hardening. Another durability test demonstrated stable perfor-
mance of VERSUS during 20 days at all operation points (2.2l/min
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at 80BPM to 3.6l/min at 140BPM) with low energy consumption
(3 watts) and low motor temperature (36◦C). The hydraulic per-
formance was confirmed in separate hydraulic tests.
Chronic in-vivo experience with an accumulated implantation
time of 78 days demonstrated good bio- and haemocompatibility
characteristics of VERSUS. The in-vivo experience led to various
design improvements, such as the integration of a temperature sen-
sor to detect gear malfunction and the reinforcement of the pusher
plate. The smaller driver-venting tube, the smooth PEEK housing
and the use of the Transonic 16PAX flow sensor with the JOTEC
16mm FlowNit graft led to easier handling and implantation.
Although the design improvements led to a 20% increase of the
volume of VERSUS, it is still in the same range as small continuous
flow devices, such as CorAide and VentrAssist. The hydraulic per-
formance suffices for bridge to recovery and the energy consump-
tion is extremely low compared to its competitors. With a increase
of maximum implantation time from 10 days to 37 days, it can be
stated that VERSUS is a promising small pulsatile ventricular as-
sist device.
Additional developments for in-vivo validation
The ethical commission of the district government of Cologne
allowed 40 days animal experiments with ACcor and VERSUS in
Aachen under the restriction of complete freedom of movement of
the animal seven days after the operation. A set-up which supplies
power to the pump by exchangeable batteries worn by the animal
in a backpack in combination with fulltime telemetry-monitoring of
the pump function was developed to enable this freedom of move-
ment.
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The animal room was adapted for this purpose: it was equipped
with new large cages, internet access and a surveillance camera.
Back packs for the bovine - and ovine model were developed and
successfully tested in-vivo.
Batteries and battery chargers were developed for uninterrupted
28 hour power supply. The new 89% smaller motor driver elec-
tronics allow continuous communication with the data acquisi-
tion and telemetry electronics. The data acquisition computer re-
ceives pump data by blue-tooth communication. The data are sent
through intranet for back-up. This system was tested in-vitro in
combination with a blood pump and mock loop without malfunc-
tion during one week.
Systematic design and validation steps in general
This PhD thesis presented an overview of the complete develop-
ment process of ACcor and VERSUS. It includes past - and future
development steps, because ACcor and VERSUS have not reached
design-freeze yet. Development steps in the conceptual and design
phase process were discussed and the corresponding design and
validation methods were presented.
It demonstrated that the validations and redesigns, discussed in
the present PhD thesis, are only a small part of the entire deve-
lopment. Therefore, a brief introduction of further development
stages was presented, because experience at the Helmholtz Insti-
tute shows that a project is often transferred into the industry
after successful validation of the blood pump in a statistical series
of animal experiments. The development of the device is continued
in the industry to reach design freeze: the stage, which obviates
the need for further design alterations as it is assumed that the
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current design will successfully fulfill all requirements for the pro-
duct. Then the production of the device is setup and fixed, after
which the market approval phase is entered. In Europe, accredited
institutions (Notified Bodies) control the compliance of the manu-
facturer and device to the Medical Device Directive (93/42/EEC)
(law for protection of patients). After compliance has been deter-
mined, market approval is obtained.
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Discussion and perspective
Even though the REMATCH study demonstrated that mechan-
ical circulatory support is an effective alternative for conventional
treatments, there is a large discrepancy between the number of pa-
tients and the actual number of blood pump implantations. Main
causes for this discrepancy are large system-size, thrombogenicity,
haemolysis, durability, aggressive operations and system costs.
Alternatives, such as stem cell therapy, cloning and xeno - trans-
plantation are still in very early development stages. More com-
petition for ACcor and VERSUS is to be expected from rotary
blood pumps, being smaller, having only one moving component
and which also lack the need for valves and compliance chambers.
The third generation rotary blood pumps are even free from wear
having magnetic levitated rotors. Still the long term influence of
non pulsatile systems on the cardiovascular system and organs re-
mains a debate.
Besides the above mentioned complications with all blood pumps,
the main focus of future development of ACcor should be the reduc-
tion of the moving and rotating components of the gear. Especially
if five year lifetime for destination therapy is required. Systems on
the market, such as NovaCor, Heartmate, Lionheart and Abiocor,
have all very few moving components.
For VERSUS, this aspect is less critical as it has less moving
components and its goal lifetime is one year. The main focus for
VERSUS is extensive wear tests and chronic animal experiments to
obtain statistical data about the reliability and haemocompatibi-
lity, after which the project could be transferred into the industry.
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A Clinical trial of AbioCor
The clinical trial of the AbioCor Total Artificial Heart (TAH)
(AbioMed, Danvers, Massachusetts, USA) was performed under
the supervision of the Food and Drug Administration (FDA) (Dow-
ling RD, 2000), (Dowling RD, 2003).
The AbioCor is approved under Humanitarian Device Exemption
(HDE) on September 5th 2006. AbioMed is allowed perform hu-
man implants with the AbioCor TAH. But under HDE approval,
the FDA may request a panel review of the post-approval study
data. It is estimated that under HDE approval, a population of
approximately 4000 patients each year can be treated in the United
States.
127
A Clinical trial of AbioCor
No. Sex Age Diag. Implanted Days Stat COD
1 M 58 ICM 07.02.2001 151 died CVA
2 M 70 ICM 13.09.2001 512 died Diaphragm wear
3 M 68 ICM 26.09.2001 142 died CVA
4 M 74 ICM 17.10.2001 53 died MOSF
5 M 51 IdCM 05.11.2001 293 died CVA
6 M 79 ICM 27.11.2001 0 died Bleeding
7 M 61 ICM 10.04.2002 0 died Thrombosis
8 M 79 ICM 07.01.2003 100 died MOSF
9 M 65 ICM 22.01.2003 53 died CVA
10 M 69 ICM 24.02.2003 110 died MOSF
11 M 64 ICM 01.05.2003 114 died CVA
12 M 63 ICM 20.02.2004 85 died MOSF
13 M 73 ICM 03.05.2004 147 died Device related
14 M 73 ICM 24.05.2004 166 died MOSF
Table A.1: Results of the clinical trial of the AbioCor TAH.
CVA: Cerebrovascular accident, ICM: Ischemic cardiomy-
opathy, IdCM: Idiopathic Cardiomyopathy, MOSF: Multi-
ple Organ System Failure. (No.5) (Frazier OH, 2004) (Abio-
med).
Clinic Operation No.
Jewish hospital, Louisville, Ky 1,2,7,8,9,13,14
Texas Heart Institute, Houston, Tex 3,6,10,11,12
UCLA, Los Angeles, Calif. 4
Hahnemann Univ. Hosp., Philadelphia, Pa. 5
Table A.2: Clinics involved in clinical trial of AbioCor.
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B ACcor: assembly drawings
Nr. Component Nr. Component
(1) Outlet connector (29) Bearing
(2) Screw connector (30) Distance ring piston rod
(3) Outlet valve (31) Eccentric tappet
(4) Span ring (32) Screw Crank
(5) Internal gear stage 1 (33) Pump chamber right side
(6) Planetary gear wheel 1st stage (34) Shaft Crank
(7) Motor housing (35) Bearing
(8) Bearing (36) Valve ring
(9) Sun wheel 1st stage (37) Cuff ring
(10) Upper pin (38) Housing
(11) Quarter rotary closure part 1 (39) Teflon shim
(12) Quarter rotary closure part 2 (40) Left piston rod
(13) Bottom pin (41) Planetary gear wheel 2nd stage
(14) Screw cage (42) Teflon shim
(15) Shaft bearing carrier (43) Sun wheel 2nd stage
(16) Bearing (44) Bearing
(17) Bearing (45) Teflon shim
(18) Distance ring (46) Seal
(19) Stator (47) Ring
(20) Cage (48) Pump chamber left
(21) Rotor (49) Pusher plate left
(22) Planetary gear bolts (50) Bearing
(23) Distance ring bearing (51) Screw pusher plate
(24) Internal gear wheel, 2nd stage (52) Left diaphragm
(25) Gear frame (53) Right diaphragm
(26) Bearing (54) Right pusher plate
(27) Crank (55) Teflon shim
(28) Right piston rod
Table B.1: Components of ACcor
130
Figure B.1: Front view of ACcor pump unit
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Figure B.2: Bottom view of ACcor pump unit
132
Figure B.3: Side view of ACcor pump unit
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C VERSUS: assembly
drawings
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C VERSUS: assembly drawings
Nr. Component Nr. Component
(1) Middle Housing (27) Rotor
(2) Base plate (28) Bearing
(3) Rocker Block (29) Shaft bearing carrier
(4) Rocker (30) Distance ring
(5) Drive gear (31) Bearing
(6) Swash plate (32) Sun wheel
(7) Swash plate carrier (33) Top housing
(8) Bearings (34) Seal
(9) Swash bolt (35) Pump chamber
(10) Bearing (36) Pusher plate
(11) Intermediate gear (37) Diaphragm
(12) Intermediate gear shaft (38) Inlet connector / valve
(13) Bearing (39) O-Ring seal
(14) Pinion gear (40) Outlet connector / valve
(15) Cage (41) Shaft rocker
(16) Planetary gear bolts (42) Couple
(17) Bearing (43) Pusher plate carrier
(18) Distance ring (44) Screw shaft
(19) O-Ring Seal (45) Teflon shim
(20) Teflon shim (46) Shaft
(21) Bearing (47) Fixture holder
(22) Internal gear (48) Fixture
(23) Planetary gear (49) Fixture shafts
(24) Stator (50) Slide bearing
(25) Motor housing (51) Couple shaft
(26) Magnets
Table C.1: Components of VERSUS
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Figure C.1: Front view of VERSUS pump unit
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C VERSUS: assembly drawings
Figure C.2: Top view of VERSUS pump unit
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Abbreviations
CAD Computer Aided Design
CAM Computer Aided Manufacturing
CB Certification Body
CFD Computational Fluid Dynamics
CHF Congestive Heart Failure
DAQ Data Acquisition
EMF Electro Motor Force
FDA Food and Drug Administration
FEM Finite Element Methods
HDE Humanitarian Device Exemption
HIA Helmholtz Institute Aachen
KaFör Kaufmann - Förster
MDD Medical Device Directive
NB Notified Body
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Abbreviations
NYHA New York Heart Association
PEEK Poly-Ether-Ether-Ketone
PUR Polyurethane
TAH Total Artificial Heart
TET Transcutaneous Energy Transmission
VAD Ventricular Assist Device
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